CN109575045B - Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof - Google Patents
Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof Download PDFInfo
- Publication number
- CN109575045B CN109575045B CN201710907030.4A CN201710907030A CN109575045B CN 109575045 B CN109575045 B CN 109575045B CN 201710907030 A CN201710907030 A CN 201710907030A CN 109575045 B CN109575045 B CN 109575045B
- Authority
- CN
- China
- Prior art keywords
- piperidinyl
- piperazinyl
- methylpiperazinyl
- hydrogen
- carbonyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明涉及噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用。具体地,涉及一类具有ALK和/或c‑Met选择性抑制活性的化合物,其制备方法、包含该化合物的药物组合物,以及这些化合物在制备用于预防或治疗与生物体内渐变性淋巴瘤激酶相关的疾病的药物中的用途,以及在制备用于预防或治疗与血管新生或癌转移相关的疾病的药物中的用途,尤其是在制备用于预防或治疗肿瘤生长与转移的药物中的用途。
The present invention relates to a thienopyrimidine compound, its preparation method, pharmaceutical composition and its application. Specifically, it relates to a class of compounds with ALK and/or c-Met selective inhibitory activity, a preparation method thereof, a pharmaceutical composition comprising the compound, and the preparation of these compounds for the prevention or treatment of progressive lymphoma in vivo Use in medicaments for kinase-related diseases, and use in the preparation of medicaments for preventing or treating diseases related to angiogenesis or cancer metastasis, especially in the preparation of medicaments for preventing or treating tumor growth and metastasis use.
Description
技术领域technical field
本发明涉及药物化学领域,具体地,涉及一类具有ALK和/或c-Met选择性抑制活性的化合物,其制备方法、包含该化合物的药物组合物,以及这些化合物在制备用于预防或治疗与生物体内渐变性淋巴瘤激酶相关的疾病的药物中的用途,以及在制备用于预防或治疗与血管新生或癌转移相关的疾病的药物中的用途,尤其是在制备用于预防或治疗肿瘤生长与转移的药物中的用途。The present invention relates to the field of medicinal chemistry, in particular, to a class of compounds with ALK and/or c-Met selective inhibitory activity, a preparation method thereof, a pharmaceutical composition comprising the compound, and preparation of these compounds for prevention or treatment Use in medicines for diseases related to progressive lymphoma kinase in vivo, and in the preparation of medicines for the prevention or treatment of diseases related to angiogenesis or cancer metastasis, especially in the preparation of medicines for the prevention or treatment of tumors Use in growth and transfer drugs.
背景技术Background technique
渐变性淋巴瘤酶(ALK)是一种受体酪氨酸激酶,隶属于胰岛素受体超家族。蛋白结构从N端到C端依次为胞外受体结构域、跨膜区和胞内酪氨酸激酶结构域。正常的ALK蛋白主要在中枢神经和末梢神经系统中表达,人体中ALK基因的表达水平随脑部发育程度呈现下降趋势,尤其在成熟脑组织中的量很少。而在其他系统尤其是造血体统中尚未发现ALK的表达,证明其表达和分布具有一定的区域性。Gradient lymphoma kinase (ALK) is a receptor tyrosine kinase that belongs to the insulin receptor superfamily. The protein structure consists of extracellular receptor domain, transmembrane domain and intracellular tyrosine kinase domain from N-terminal to C-terminal. Normal ALK protein is mainly expressed in the central nervous system and peripheral nervous system. The expression level of ALK gene in human body shows a downward trend with the degree of brain development, especially in mature brain tissue. However, the expression of ALK has not been found in other systems, especially the hematopoietic lineage, which proves that its expression and distribution have a certain regionality.
正常情况下,人源的ALK基因可以编码1602个氨基酸、200kDa的I型穿膜蛋白ALK,但该基因通常处于休眠状态。在与其他基因发生融合的情况下,ALK基因可以成为非常强力的致癌基因。目前已经发现的可以与ALK基因发生融合的基因有核磷蛋白基因(NPM,渐变性大细胞淋巴瘤ALCL),棘皮动物微管相关蛋白样4基因(EML4,非小细胞肺癌NSCLC),原肌球蛋白3基因(TPM3,炎性肌纤维母细胞瘤IMT)等等(Nat.Rev.Cancer,2008,8,11–23.;Nat.Rev.Cancer,2013,13,685-700.;Expert Opin.Ther.Pat.,2014.24(4):p.417-42.)。Under normal circumstances, the human ALK gene can encode the 1602 amino acid, 200kDa type I transmembrane protein ALK, but the gene is usually in a dormant state. When fused with other genes, the ALK gene can become a very powerful oncogene. The genes that have been found to be fused with the ALK gene include the nucleophosmin gene (NPM, ALCL with progressive large cell lymphoma), the echinoderms microtubule-associated protein-like 4 gene (EML4, non-small cell lung cancer NSCLC), the protomyocytes Globulin 3 gene (TPM3, inflammatory myofibroblastic tumor IMT) etc. (Nat. Rev. Cancer, 2008, 8, 11-23.; Nat. Rev. Cancer, 2013, 13, 685-700.; Expert Opin. Ther .Pat., 2014.24(4):p.417-42.).
在非小细胞肺癌中,主要是与EML4基因发生融合,该融合基因(EML4-ALK)在NSCLC中的发生率为4%-7%。随着对非小细胞肺癌(NSCLC)在分子生物学上的研究不断深入,基于分子标记物(biomarker)的个性化治疗已经从实验室走向了临床,并在对晚期非小细胞肺癌患者的治疗上取得了较大的临床进展。这意味着除了对NSCLC可以进行传统的病理组织学分类外,还可以根据具体患者的不同分子标记物的不同表达水平进行分子表型分类。NSCLC患者在接受治疗前进行相关分子标记物检测。在临床上医生可以根据其肿瘤分子表型特征进行有针对性的治疗,从而提高治疗效果。在这样的背景下,以与肿瘤发生、发展密切相关的驱动基因或其编码蛋白为靶点研究开发新药物已经成为抗肿瘤药物研究的热点。In non-small cell lung cancer, it is mainly fused with EML4 gene, and the incidence of this fusion gene (EML4-ALK) in NSCLC is 4%-7%. With the deepening of molecular biology research on non-small cell lung cancer (NSCLC), personalized therapy based on molecular markers (biomarker) has moved from the laboratory to the clinic, and is being used in the treatment of patients with advanced non-small cell lung cancer. Significant clinical progress has been made. This means that in addition to the traditional histopathological classification of NSCLC, molecular phenotype classification can also be performed based on the different expression levels of different molecular markers in specific patients. NSCLC patients were tested for relevant molecular markers before receiving treatment. In clinic, doctors can carry out targeted treatment according to the molecular phenotype characteristics of the tumor, thereby improving the therapeutic effect. In this context, the research and development of new drugs targeting the driver genes or their encoded proteins that are closely related to the occurrence and development of tumors has become a hot spot in anti-tumor drug research.
目前,美国食品和药物管理局已经批准辉瑞(Pfizer)公司开发的小分子抑制剂CrizotInib(J.Thorac.Oncol.,2010.5(12):p.2044-6.)、诺华(Novartis)公司开发的Ceritinib(J.Med.Chem.,2013.56(14):p.5675-90.)、Chugai PharmaceutICal开发的Alectinib(Cancer Lett.,2014.351(2):p.215-21.)上市。但是,也有临床研究表明有部分患者对Crizotinib已经出现了耐药性,同时,Crizotinib的生物利用度也有待提高。Ceritinib可以针对部分对Crizotinib出现耐药性或不耐受的患者。因此,临床实践中非常需要它们的替代化合物已提高药效和应对耐药性。At present, the US Food and Drug Administration has approved the small molecule inhibitor CrizotInib (J.Thorac.Oncol., 2010.5(12):p.2044-6.) developed by Pfizer, CrizotInib developed by Novartis Ceritinib (J.Med.Chem., 2013.56(14):p.5675-90.) and Alectinib (Cancer Lett., 2014.351(2):p.215-21.) developed by Chugai PharmaceutICal were launched. However, there are also clinical studies showing that some patients have developed resistance to Crizotinib, and the bioavailability of Crizotinib needs to be improved. Ceritinib can target some patients who have developed resistance or intolerance to Crizotinib. Therefore, their replacement compounds are highly needed in clinical practice to improve drug efficacy and address drug resistance.
发明内容SUMMARY OF THE INVENTION
本发明发明人为了寻找新ALK抑制剂,经过广泛深入的研究,设计、合成了一系列结构新颖、安全性高、对多种酪氨酸激酶(EGFR、PDGFR、c-Met等),尤其是对ALK具有较高的活性的多取代噻吩并嘧啶(噻吩[3,2-d]嘧啶)衍生物,并且研究了这一类新型衍生物的抗肿瘤活性。In order to search for new ALK inhibitors, the inventors of the present invention have designed and synthesized a series of novel structures, high safety, and various tyrosine kinases (EGFR, PDGFR, c-Met, etc.), especially Multi-substituted thienopyrimidine (thiophene[3,2-d]pyrimidine) derivatives with high activity to ALK, and the antitumor activity of this new class of derivatives was studied.
化合物的通式:The general formula of the compound:
其中取代基和符号的定义下面详细说明。The definitions of the substituents and symbols therein are explained in detail below.
本发明的一个目的是提供一类具有ALK和/或c-Met选择性抑制活性的化合物及其药学上可接受的盐或药学上可接受的溶剂合物;An object of the present invention is to provide a class of compounds with ALK and/or c-Met selective inhibitory activity and pharmaceutically acceptable salts or pharmaceutically acceptable solvates thereof;
本发明的另一个目的是提供一种上述化合物的制备方法;Another object of the present invention is to provide a preparation method of the above compound;
本发明的另一个目的是提供一种包含上述化合物的药物组合物;Another object of the present invention is to provide a pharmaceutical composition comprising the above compound;
本发明的另一个目的是提供上述化合物在制备用于预防或治疗与生物体内渐变性淋巴瘤酶相关的伴随细胞异常增殖、形态变化以及运动功能亢进等的疾病的药物中的用途,以及在制备用于预防或治疗与血管新生或癌转移相关的疾病的药物中的用途,尤其是在制备用于预防或治疗肿瘤生长与转移的药物中的用途。Another object of the present invention is to provide the use of the above-mentioned compound in the preparation of a medicament for the prevention or treatment of diseases associated with progressive lymphoma enzymes in vivo accompanied by abnormal cell proliferation, morphological changes, and hyperkinesia, etc., and in the preparation of Use in medicaments for preventing or treating diseases related to angiogenesis or cancer metastasis, especially in preparing medicaments for preventing or treating tumor growth and metastasis.
附图描述Description of drawings
图1描述化合物IB-1在EML4-ALK(G1202R)-Ba/F3裸鼠异种移植瘤模型中显著抑制肿瘤生长。A)化合物IB-1分别在60mg/kg(1次/天)、40mg/kg(2次/天,bid)剂量,口服给药,连续给药10天,肿瘤生长均被显著抑制;B)在给药过程中,给药组小鼠体重均未出现明显变化,表明对小鼠对药物有较好的耐受,IB-1无明显毒副作用。Figure 1 depicts that compound IB-1 significantly inhibited tumor growth in the EML4-ALK(G1202R)-Ba/F3 nude mouse xenograft tumor model. A) Compound IB-1 was administered orally at 60 mg/kg (1 time/day) and 40 mg/kg (2 times/day, bid), respectively, for 10 consecutive days, the tumor growth was significantly inhibited; B) During the administration process, the body weight of the mice in the administration group did not change significantly, indicating that the mice had a good tolerance to the drug, and IB-1 had no obvious side effects.
图2描述化合物IB-1在非小细胞肺癌H3122细胞裸鼠异种移植瘤模型中显著抑制肿瘤生长。A)化合物IB-1分别在30mg/kg(1次/天)、50mg/kg(1次/天)剂量,口服给药,连续给药18天,肿瘤生长均被显著抑制;B)在给药过程中,给药组小鼠体重均未出现明显变化,表明对小鼠对药物有较好的耐受,IB-1无明显毒副作用。Figure 2 depicts that Compound IB-1 significantly inhibited tumor growth in a non-small cell lung cancer H3122 cell nude mouse xenograft tumor model. A) Compound IB-1 was administered orally at doses of 30 mg/kg (1 time/day) and 50 mg/kg (1 time/day), respectively, for 18 consecutive days, the tumor growth was significantly inhibited; B) After administration During the course of the drug, the body weight of the mice in the administration group did not change significantly, indicating that the mice had a good tolerance to the drug, and IB-1 had no obvious toxic and side effects.
发明详述Detailed description of the invention
本发明是通过下面技术方案实现的。The present invention is achieved through the following technical solutions.
第一方面,本发明提供了一种下面通式I表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a first aspect, the present invention provides a compound represented by the following general formula I, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中:R’为氢,氯或溴;Wherein: R' is hydrogen, chlorine or bromine;
R1选自:R1 is selected from :
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,N-甲基-4-哌啶基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxyalkyl, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, N-methyl-4-piperidine base,
(3)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(3) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(4)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(4) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(5)哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,吗啉基,3,5-二甲基吗啉基,硫啡啉基,四氢吡咯基,3-N,N-二甲基氨基四氢吡咯基,3-N,N-二乙基氨基四氢吡咯基,4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,2-氧代-哌嗪-4-基,咪唑基,4-甲基咪唑基,(5) piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diisopropylaminopiperidinyl, 4-Hydroxypiperidinyl, morpholinyl, 3,5-dimethylmorpholinyl, thiophenaryl, tetrahydropyrrolyl, 3-N,N-dimethylaminotetrahydropyrrolyl, 3-N ,N-Diethylaminotetrahydropyrrolyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxy Carbonylpiperazinyl, 4-methanesulfonylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl) Piperazinyl, 4-(2-N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-Diethylaminoethyl)piperazinyl, 4-(3-N ,N-dimethylaminopropyl)piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 2-oxo-piperazin-4-yl, imidazolyl, 4 - methylimidazolyl,
(6)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(6) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl-4-piperidinyl)piperazinyl,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪-1-基磺酰基,4-乙酰基哌嗪-1-基磺酰基,4-叔丁氧羰基哌嗪-1-基磺酰基,4-(2-羟基乙基)哌嗪-1-基磺酰基,4-(2-氰基乙基)哌嗪-1-基磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪-1-基磺酰基,4-(2-N,N-二乙基乙基)哌嗪-1-基磺酰基,4-(3-羟基丙基)哌嗪-1-基磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪-1-基磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪-1-基磺酰基,吗啉-1-基磺酰基,3,5-二甲基吗啉-1-基磺酰基,4-(四氢吡咯基)哌啶-1-基磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪-1-基磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazin-1-ylsulfonyl, 4-acetylpiperazin-1-ylsulfonyl , 4-tert-butoxycarbonylpiperazin-1-ylsulfonyl, 4-(2-hydroxyethyl)piperazin-1-ylsulfonyl, 4-(2-cyanoethyl)piperazin-1-yl Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazin-1-ylsulfonyl, 4-(2-N,N-diethylethyl)piperazin-1-ylsulfonyl Acyl, 4-(3-hydroxypropyl)piperazin-1-ylsulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazin-1-ylsulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazin-1-ylsulfonyl, morpholin-1-ylsulfonyl, 3,5-dimethylmorpholin-1-ylsulfonyl, 4-(tetrahydro Pyrrolyl)piperidin-1-ylsulfonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethylpiperazin-1-yl) Piperidin-1-ylsulfonyl, 4-(4-acetyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazine-1 -Sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,4-(四氢吡咯基)哌啶基--1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪-1-基羰基,4-(2-N,N-二乙基氨基乙基)哌嗪-1-基羰基,4-(3-羟基丙基)哌嗪-1-基羰基,4-(3-N,N-二甲基氨基丙基)哌嗪-1-基羰基,4-(3-N,N-二乙基氨基丙基)哌嗪-1-基羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-哌嗪-1-基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪-1-基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-Hydroxypiperidinyl-1-carbonyl, 4-N,N-Dimethylaminopiperidinyl-1-carbonyl, 4-N,N-Diethylaminopiperidinyl-1-carbonyl, 4 -(Tetrahydropyrrolyl)piperidinyl-1-carbonyl, tetrahydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N- Diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4 -tert-Butoxycarbonylpiperazinyl-1-carbonyl, 4-(2-hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4- (2-N,N-Dimethylaminoethyl)piperazin-1-ylcarbonyl, 4-(2-N,N-diethylaminoethyl)piperazin-1-ylcarbonyl, 4-(3 -Hydroxypropyl)piperazin-1-ylcarbonyl, 4-(3-N,N-dimethylaminopropyl)piperazin-1-ylcarbonyl, 4-(3-N,N-diethylamino Propyl)piperazin-1-ylcarbonyl, morpholinyl-1-carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperyl Perid-1-ylcarbonyl, 4-(4-ethyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-piperazin-1-yl)piperidinyl-1- carbonyl, 4-(N-methyl-4-piperidinyl)piperazin-1-ylcarbonyl,
(9)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(9) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(10)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪-1-基甲酰氨基,4-乙基哌嗪-1-基甲酰氨基,4-乙酰基哌嗪-1-基甲酰氨基,4-叔丁氧羰基哌嗪-1-基甲酰氨基,4-(2-羟基乙基)哌嗪-1-基甲酰氨基,4-(2-氰基乙基)哌嗪-1-基甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪-1-基甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪-1-基甲酰氨基,4-(3-羟基丙基)哌嗪-1-基甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪-1-基甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪-1-基甲酰氨基,吗啉-1-基甲酰氨基,3,5-二甲基吗啉-1-基甲酰氨基,4-(四氢吡咯基)哌啶-1-基甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶-1-基甲酰氨基,4-(4-乙基哌嗪-1-基)哌啶-1-基甲酰氨基,4-(4-乙酰基-哌嗪-1基)哌啶-1-基甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪-1-基甲酰氨基;或(10) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazin-1-ylcarboxamido, 4-ethylpiperazin-1-ylcarboxamido , 4-Acetylpiperazin-1-ylcarboxamido, 4-tert-butoxycarbonylpiperazin-1-ylcarboxamido, 4-(2-hydroxyethyl)piperazin-1-ylcarboxamido, 4-(2-cyanoethyl)piperazin-1-ylcarboxamido, 4-(2-N,N-dimethylaminoethyl)piperazin-1-ylcarboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazin-1-ylcarboxamido, 4-(3-hydroxypropyl)piperazin-1-ylcarboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazin-1-ylcarboxamido, 4-(3-N,N-diethylaminopropyl)piperazin-1-ylcarboxamido, morpholin-1-ylmethyl amido, 3,5-dimethylmorpholin-1-ylcarboxamido, 4-(tetrahydropyrrolyl)piperidin-1-ylcarboxamido, 4-(4-methyl-piperazine-1 -yl)piperidin-1-ylcarboxamido, 4-(4-ethylpiperazin-1-yl)piperidin-1-ylcarboxamido, 4-(4-acetyl-piperazin-1yl ) piperidin-1-ylcarboxamido, 4-(N-methyl-4-piperidinyl)piperazin-1-ylcarboxamido; or
(11)氨基乙酰氨基,2-二甲氨基乙酰氨基,N-叔丁氧羰基乙酰氨基,N-乙酰基氨基乙酰氨基,丙烯酰氨基,环丙酰氨基,氯乙酰氨基,哌啶基乙酰氨基,4-羟基哌啶基乙酰氨基,4-N,N-二甲基氨基哌啶基乙酰氨基,4-N,N-二乙基氨基哌啶基乙酰氨基,四氢吡咯基乙酰氨基,3-N,N-二甲基氨基四氢吡咯基乙酰氨基,3-N,N-二乙基氨基四氢吡咯基乙酰氨基,4-甲基哌嗪基乙酰氨基,4-乙基哌嗪基乙酰氨基,4-乙酰基哌嗪基乙酰氨基,4-叔丁氧羰基哌嗪基乙酰氨基,4-(2-羟基乙基)哌嗪基乙酰氨基,4-(2-氰基乙基)哌嗪基乙酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基乙酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基乙酰氨基,4-(3-羟基丙基)哌嗪基乙酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基乙酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基乙酰氨基,吗啉基乙酰氨基,3,5-二甲基吗啉基乙酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基乙酰氨基,4-(4-乙基-1-哌嗪基)哌啶基乙酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基乙酰氨基,N-(N-甲基-4-哌啶基)哌嗪基乙酰氨基,4-(四氢吡咯-1-基)哌啶基乙酰氨基;2-甲基氨基乙酰氨基,2-(1-甲基乙基)氨基乙酰氨基;N-苄氧基羰基-2甲基氨基乙酰氨基;(11) Aminoacetamido, 2-dimethylaminoacetamido, N-tert-butoxycarbonylacetamido, N-acetylaminoacetamido, acrylamido, cyclopropionamido, chloroacetamido, piperidinylacetamido , 4-Hydroxypiperidinylacetamido, 4-N,N-Dimethylaminopiperidinylacetamido, 4-N,N-Diethylaminopiperidinylacetamido, Tetrahydropyrrolylacetamido, 3 -N,N-dimethylaminotetrahydropyrrolylacetamido, 3-N,N-diethylaminotetrahydropyrrolylacetamido, 4-methylpiperazinylacetamido, 4-ethylpiperazinyl Acetylamino, 4-acetylpiperazinylacetamido, 4-tert-butoxycarbonylpiperazinylacetamido, 4-(2-hydroxyethyl)piperazinylacetamido, 4-(2-cyanoethyl) Piperazinylacetamido, 4-(2-N,N-dimethylaminoethyl)piperazinylacetamido, 4-(2-N,N-diethylaminoethyl)piperazinylacetamido, 4-(3-Hydroxypropyl)piperazinylacetamido, 4-(3-N,N-dimethylaminopropyl)piperazinylacetamido, 4-(3-N,N-diethylamino Propyl)piperazinylacetamido, morpholinoacetamido, 3,5-dimethylmorpholinoacetamido, 4-(4-methyl-piperazin-1-yl)piperidinylacetamido, 4 -(4-Ethyl-1-piperazinyl)piperidinylacetamido, 4-(4-acetyl-1-piperazinyl)piperidinylacetamido, N-(N-methyl-4-piperidine Peridyl) piperazinylacetamido, 4-(tetrahydropyrrol-1-yl)piperidinylacetamido; 2-methylaminoacetamido, 2-(1-methylethyl)aminoacetamido; N- benzyloxycarbonyl-2methylaminoacetamido;
(12)Z2与Z3或Z3与Z4形成含氧的取代或未取代的五元环或六元环;取代基可以选自与Z1相同的上述取代基,(12) Z 2 and Z 3 or Z 3 and Z 4 form an oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring; the substituents can be selected from the same substituents as Z 1 above,
(13)Z2与Z3或Z3与Z4形成含氮的取代或未取代的五元环或六元环;取代基可以选自与Z1相同的上述取代基,(13) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen-containing substituted or unsubstituted five-membered ring or six-membered ring; the substituents can be selected from the same substituents as Z 1 above,
3)其中Z2,Z3,Z4,Z5与上述2)中定义相同;3) Wherein Z 2 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2);
4)其中Z1,Z3,Z4,Z5与上述2)中定义相同;4) Wherein Z 1 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2);
A为直接键或亚甲基;A is a direct bond or methylene;
X为NH,S或O;X is NH, S or O;
R2选自:R 2 is selected from:
1)C1-C6烷基,C2-C6烯基,C2-C6炔基,C3-C6环烷基;1) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl;
2)其中A1,A2,A3,A4,A5各自独立地选自:2) wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,叔丁磺酰基,二甲氨基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,二甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基,(2) Methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, tert-butanesulfonyl , dimethylaminosulfonyl, mesylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl , methylaminocarbonyl, dimethylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethyl phosphinoyl, diisopropylphosphinoyl,
3) 3)
其中,Y为NH,S或O原子,where Y is an NH, S or O atom,
A6,A7,A8,A9,A10,A11各自独立地选自:A 6 , A 7 , A 8 , A 9 , A 10 , A 11 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, Propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl;
4) 4)
其中A12选自:where A 12 is selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,甲基亚磺酰基,乙基亚磺酰基,异丙基亚磺酰基,甲基磺酰基,乙基磺酰基,异丙基磺酰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, Propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl , ethylsulfonyl, isopropylsulfonyl;
Y2,Y3,Y4选自以下组合:Y 2 , Y 3 , Y 4 are selected from the following combinations:
Y2为N,Y3为N-A13,Y4为CH或N;Y 2 is N, Y 3 is NA 13 , and Y 4 is CH or N;
Y2为N,Y3为C-A13,Y4为N,O或S;Y 2 is N, Y 3 is CA 13 , and Y 4 is N, O or S;
Y2为O或S,Y3为N-A13,Y4为CH;Y 2 is O or S, Y 3 is NA 13 , and Y 4 is CH;
Y2为O或S,Y3为C-A13,Y4为N;和Y 2 is O or S, Y 3 is CA 13 , and Y 4 is N; and
Y2为C,Y3为N-A13,Y4为O或S;Y 2 is C, Y 3 is NA 13 , and Y 4 is O or S;
Y2为C,Y3为N-A13,Y4为N;Y 2 is C, Y 3 is NA 13 , and Y 4 is N;
其中A13为氢,C1-C6烷基,C2-C6烯基,C2-C6炔基,C3-C6环烷基;Wherein A 13 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl;
5)哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,吗啉基,3,5-二甲基吗啉基,硫啡啉基,四氢吡咯基,3-N,N-二甲基氨基四氢吡咯基,3-N,N-二乙基氨基四氢吡咯基,4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基。5) piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diisopropylaminopiperidinyl, 4 -Hydroxypiperidyl, morpholinyl, 3,5-dimethylmorpholinyl, thiophanolinyl, tetrahydropyrrolyl, 3-N,N-dimethylaminotetrahydropyrrolyl, 3-N, N-Diethylaminotetrahydropyrrolyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonyl Piperazinyl, 4-Methanesulfonylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl Azinyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N, N-dimethylaminopropyl)piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl.
在一些实施方案中,R’为氢。In some embodiments, R' is hydrogen.
在一些实施方案中,其中,R1选自:In some embodiments, wherein R 1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-(N-甲基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, C3-C6 cycloalkyl, 4-N,N-dimethylaminocyclohexyl, 4-N, N-Diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4-piperidinyl, 1,3-dimethyl -5-pyrazolyl, 1-(N-methyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,硝基,(1) Hydrogen, Fluorine, Chlorine, Bromine, Nitro,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,N-甲基-4-哌啶基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxyalkyl, C1-C6 fluoroalkyl, C1-C6 fluoroalkoxy, N-methyl-4-piperidine base,
(3)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,(3) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethylpiperidine-4-amino,
(4)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,(4) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-diisopropylaminopropoxy, 3-(4-acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenidylpropoxy oxy, 3-piperidinylpropoxy, pyridin-2-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen substituted phenylmethoxy,
(5)哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,吗啉基,3,5-二甲基吗啉基,硫啡啉基,四氢吡咯基,3-N,N-二甲基氨基四氢吡咯基,3-N,N-二乙基氨基四氢吡咯基,4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,2-氧代-哌嗪-4-基,咪唑基,4-甲基咪唑基,(5) piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diisopropylaminopiperidinyl, 4-Hydroxypiperidinyl, morpholinyl, 3,5-dimethylmorpholinyl, thiophenaryl, tetrahydropyrrolyl, 3-N,N-dimethylaminotetrahydropyrrolyl, 3-N ,N-Diethylaminotetrahydropyrrolyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-(2- Hydroxyethyl)piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 2-oxo-piperazin-4-yl, imidazolyl, 4-methylimidazolyl,
(6)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(6) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-di Methylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N , N-dimethylaminopropyl) piperazinyl) piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl) piperidinyl, 4-(N-methyl-4- piperidinyl)piperazinyl, 4-(N-ethyl-4-piperidinyl)piperazinyl,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,3-N,N-二甲基四氢吡咯-1-基磺酰基,3-N,N-二乙基氨基四氢吡咯-1-基磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪-1-基磺酰基,4-乙酰基哌嗪-1-基磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,N-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪-1-基磺酰基,4-(3-羟基丙基)哌嗪-1-基磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪-1-基磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪-1-基磺酰基,4-(4-乙酰基哌嗪-1-基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪-1-基磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 3-N,N-dimethyltetrahydropyrrol-1-ylsulfonyl, 3-N,N-di Ethylaminotetrahydropyrrol-1-ylsulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazin-1-ylsulfonyl, 4-acetylpiperazin-1-ylsulfonyl Acyl, 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, N-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- sulfonyl, 4-(3-hydroxypropyl)piperazin-1-ylsulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazin-1-ylsulfonyl, 4-( 3-N,N-Diethylaminopropyl)piperazin-1-ylsulfonyl, 4-(4-acetylpiperazin-1-yl)piperidin-1-ylsulfonyl, 4-(N- Methyl-4-piperidinyl)piperazin-1-ylsulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪-1-基羰基,4-(2-N,N-二乙基氨基乙基)哌嗪-1-基羰基,4-(3-N,N-二乙基氨基丙基)哌嗪-1-基羰基,吗啉-1-基羰基,3,5-二甲基吗啉-1-基羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基羰基,4-(N-甲基-4-哌啶基)哌嗪-1-基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazin-1-ylcarbonyl , 4-(2-N,N-diethylaminoethyl)piperazin-1-ylcarbonyl, 4-(3-N,N-diethylaminopropyl)piperazin-1-ylcarbonyl, ? Linen-1-ylcarbonyl, 3,5-dimethylmorpholin-1-ylcarbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4- Acetyl-1-piperazinyl)piperidin-1-ylcarbonyl, 4-(N-methyl-4-piperidinyl)piperazin-1-ylcarbonyl,
(9)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,叔丁氧基羰基,(9) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl,
(10)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,4-乙酰基哌嗪-1-基甲酰氨基,4-(2-羟基乙基)哌嗪-1-基甲酰氨基,4-(2-氰基乙基)哌嗪-1-基甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪-1-基甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪-1-基甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪-1-基甲酰氨基,吗啉-1-基甲酰氨基,4-(4-乙酰基哌嗪-1-基)哌啶-1-基甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪-1-基甲酰氨基;或(10) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, piperidinyl-1-carboxamido , 4-Hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-diethylaminopiperidinyl-1- Formamido, 4-acetylpiperazin-1-ylcarboxamido, 4-(2-hydroxyethyl)piperazin-1-ylcarboxamido, 4-(2-cyanoethyl)piperazine- 1-ylcarboxamido, 4-(2-N,N-dimethylaminoethyl)piperazin-1-ylcarboxamido, 4-(3-N,N-dimethylaminopropyl)piperidine Azin-1-ylcarboxamido, 4-(3-N,N-diethylaminopropyl)piperazin-1-ylcarboxamido, morpholin-1-ylcarboxamido, 4-(4- Acetylpiperazin-1-yl)piperidin-1-ylcarboxamido, 4-(N-methyl-4-piperidinyl)piperazin-1-ylcarboxamido; or
(11)氨基乙酰氨基,N-叔丁氧羰基乙酰氨基,N-乙酰基氨基乙酰氨基,丙烯酰氨基,环丙酰氨基,氯乙酰氨基,哌啶基乙酰氨基,4-羟基哌啶基乙酰氨基,4-N,N-二甲基氨基哌啶基乙酰氨基,4-N,N-二乙基氨基哌啶基乙酰氨基,3-N,N-二甲基氨基四氢吡咯基乙酰氨基,N-乙基哌嗪基乙酰氨基,4-乙酰基哌嗪基乙酰氨基,4-叔丁氧羰基哌嗪基乙酰氨基,4-(2-氰基乙基)哌嗪基乙酰氨基,N-(2-N,N-二甲基氨基乙基)哌嗪基乙酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基乙酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基乙酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基乙酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基乙酰氨基,4-(4-乙基-1-哌嗪基)哌啶基乙酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基乙酰氨基,N-苄氧基羰基-2甲基氨基乙酰氨基;(11) Aminoacetamido, N-tert-butoxycarbonylacetamido, N-acetylaminoacetamido, acrylamido, cyclopropionamido, chloroacetamido, piperidinylacetamido, 4-hydroxypiperidinylacetyl Amino, 4-N,N-Dimethylaminopiperidinylacetamido, 4-N,N-Diethylaminopiperidinylacetamido, 3-N,N-Dimethylaminotetrahydropyrrolylacetamido , N-ethylpiperazinylacetamido, 4-acetylpiperazinylacetamido, 4-tert-butoxycarbonylpiperazinylacetamido, 4-(2-cyanoethyl)piperazinylacetamido, N -(2-N,N-Dimethylaminoethyl)piperazinylacetamido, 4-(2-N,N-diethylaminoethyl)piperazinylacetamido, 4-(3-N, N-dimethylaminopropyl)piperazinylacetamido, 4-(3-N,N-diethylaminopropyl)piperazinylacetamido, 4-(4-methyl-piperazine-1- yl)piperidinylacetamido, 4-(4-ethyl-1-piperazinyl)piperidinylacetamido, 4-(4-acetyl-1-piperazinyl)piperidinylacetamido, N- benzyloxycarbonyl-2methylaminoacetamido;
(12)Z2与Z3或Z3与Z4形成含氧的取代或未取代的五元环或六元环;取代基可以选自与Z1相同的上述取代基,(12) Z 2 and Z 3 or Z 3 and Z 4 form an oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring; the substituents can be selected from the same substituents as Z 1 above,
(13)Z2与Z3或Z3与Z4形成含氮的取代或未取代的五元环或六元环;取代基可以选自与Z1相同的上述取代基,(13) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen-containing substituted or unsubstituted five-membered ring or six-membered ring; the substituents can be selected from the same substituents as Z 1 above,
3)其中Z2,Z3,Z4,Z5与上述2)中定义相同;3) Wherein Z 2 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2);
4)其中Z1,Z3,Z4,Z5与上述2)中定义相同。4) Wherein Z 1 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2).
在一些实施方案中,R1选自:In some embodiments, R 1 is selected from:
1)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:1) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,硝基,(1) Hydrogen, Fluorine, Chlorine, Bromine, Nitro,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,(3) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethylpiperidine-4-amino,
(4)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,,苯基甲氧基,单卤素取代苯基甲氧基,(4) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-diisopropylaminopropoxy, 3-(4-acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenidylpropoxy oxy, 3-piperidinylpropoxy, pyridin-2-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy,
(5)哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,吗啉基,3,5-二甲基吗啉基,硫啡啉基,四氢吡咯基,3-N,N-二甲基氨基四氢吡咯基,3-N,N-二乙基氨基四氢吡咯基,4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,2-氧代-哌嗪-4-基,咪唑基,4-甲基咪唑基,(5) piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diisopropylaminopiperidinyl, 4-Hydroxypiperidinyl, morpholinyl, 3,5-dimethylmorpholinyl, thiophenaryl, tetrahydropyrrolyl, 3-N,N-dimethylaminotetrahydropyrrolyl, 3-N ,N-Diethylaminotetrahydropyrrolyl, 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-(2- Hydroxyethyl)piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 2-oxo-piperazin-4-yl, imidazolyl, 4-methylimidazolyl,
(6)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(6) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-di Methylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(3-N,N- Dimethylaminotetrahydropyrrolyl)piperidyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl-4-piperidinyl)piperazinyl,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N- Diethylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1- Sulfonyl, 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl- 1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1- Sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carbonyl , 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, Linoyl-1-carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-carbonyl,
(9)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,叔丁氧基羰基,(9) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, tert-butoxycarbonyl,
(10)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(10) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, piperidinyl-1-carboxamido , 4-Hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-diethylaminopiperidinyl-1- Formamido, 4-acetylpiperazinyl-1-carboxamido, 4-(2-hydroxyethyl)piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinido -1-Carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-N,N-dimethylaminopropyl)piperazine Azinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-carboxamido, 4-(4- Acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl-4-piperidinyl)piperazinyl-1-carboxamido; or
(11)氨基乙酰氨基,N-叔丁氧羰基乙酰氨基,N-乙酰基氨基乙酰氨基,丙烯酰氨基,环丙酰氨基,氯乙酰氨基,哌啶基乙酰氨基,4-羟基哌啶基乙酰氨基,4-N,N-二甲基氨基哌啶基乙酰氨基,4-N,N-二乙基氨基哌啶基乙酰氨基,3-N,N-二甲基氨基四氢吡咯基乙酰氨基,4-乙基哌嗪基乙酰氨基,4-乙酰基哌嗪基乙酰氨基,4-叔丁氧羰基哌嗪基乙酰氨基,4-(2-氰基乙基)哌嗪基乙酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基乙酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基乙酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基乙酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基乙酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基乙酰氨基,4-(4-乙基-1-哌嗪基)哌啶基乙酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基乙酰氨基,N-苄氧基羰基-2甲基氨基乙酰氨基;(11) Aminoacetamido, N-tert-butoxycarbonylacetamido, N-acetylaminoacetamido, acrylamido, cyclopropionamido, chloroacetamido, piperidinylacetamido, 4-hydroxypiperidinylacetyl Amino, 4-N,N-Dimethylaminopiperidinylacetamido, 4-N,N-Diethylaminopiperidinylacetamido, 3-N,N-Dimethylaminotetrahydropyrrolylacetamido , 4-ethylpiperazinylacetamido, 4-acetylpiperazinylacetamido, 4-tert-butoxycarbonylpiperazinylacetamido, 4-(2-cyanoethyl)piperazinylacetamido, 4 -(2-N,N-Dimethylaminoethyl)piperazinylacetamido, 4-(2-N,N-diethylaminoethyl)piperazinylacetamido, 4-(3-N, N-dimethylaminopropyl)piperazinylacetamido, 4-(3-N,N-diethylaminopropyl)piperazinylacetamido, 4-(4-methyl-piperazine-1- yl)piperidinylacetamido, 4-(4-ethyl-1-piperazinyl)piperidinylacetamido, 4-(4-acetyl-1-piperazinyl)piperidinylacetamido, N- benzyloxycarbonyl-2methylaminoacetamido;
(12)Z2与Z3或Z3与Z4形成含氧的取代或未取代的五元环或六元环;取代基可以选自与Z1相同的上述取代基,(12) Z 2 and Z 3 or Z 3 and Z 4 form an oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring; the substituents can be selected from the same substituents as Z 1 above,
(13)Z2与Z3或Z3与Z4形成含氮的取代或未取代的五元环或六元环;取代基可以选自与Z1相同的上述取代基,(13) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen-containing substituted or unsubstituted five-membered ring or six-membered ring; the substituents can be selected from the same substituents as Z 1 above,
2)其中Z2,Z3,Z4,Z5与上述2)中定义相同;2) Wherein Z 2 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2);
3)其中Z1,Z3,Z4,Z5与上述2)中定义相同。3) Wherein Z 1 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2).
在一些实施方案中,A为直接键。In some embodiments, A is a direct bond.
在一些实施方案中,A为亚甲基。In some embodiments, A is methylene.
在一些实施方案中,R2选自:In some embodiments, R 2 is selected from:
1)C1-C6烷基,C2-C6烯基,C2-C6炔基,C3-C6环烷基;1) C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl;
2)其中A1,A2,A3,A4,A5各自独立地选自:2) wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro,
(2)甲硫基,乙硫基,异丙硫基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,叔丁磺酰基,二甲氨基磺酰基,甲磺酰氨基,甲氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,环丁基氨基羰基,甲氨基羰基,二甲氨基羰基,异丙氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基,(2) methylthio, ethylthio, isopropylthio, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethanesulfonyl, isopropylsulfonyl, tert-butanesulfonyl, dimethylaminosulfonyl Acyl, methanesulfonylamino, methoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, cyclobutylaminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, isopropylaminocarbonyl, Dimethylphosphinoyl, Diethylphosphinoyl, Diisopropylphosphinoyl,
3) 3)
其中,Y为NH,S或O原子,where Y is an NH, S or O atom,
A6,A7,A8,A9,A10,A11各自独立地选自:A 6 , A 7 , A 8 , A 9 , A 10 , A 11 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环戊基氨基羰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, Propylaminocarbonyl, isopropylaminocarbonyl, cyclopentylaminocarbonyl;
4) 4)
其中A12选自:where A 12 is selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丁基氨基羰基,甲基亚磺酰基,甲基磺酰基,乙基磺酰基,异丙基磺酰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropyl Aminocarbonyl, cyclobutylaminocarbonyl, methylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl;
Y2,Y3,Y4选自以下组合:Y 2 , Y 3 , Y 4 are selected from the following combinations:
Y2为N,Y3为N-A13,Y4为CH或N;Y 2 is N, Y 3 is NA 13 , and Y 4 is CH or N;
Y2为O或S,Y3为C-A13,Y4为N;和Y 2 is O or S, Y 3 is CA 13 , and Y 4 is N; and
Y2为C,Y3为N-A13,Y4为O或S;Y 2 is C, Y 3 is NA 13 , and Y 4 is O or S;
Y2为C,Y3为N-A13,Y4为N;Y 2 is C, Y 3 is NA 13 , and Y 4 is N;
其中A13为氢,C1-C6烷基,C2-C6烯基,C2-C6炔基,C3-C6环烷基;Wherein A 13 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl;
5)哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,吗啉基,3,5-二甲基吗啉基,3-N,N-二甲基氨基四氢吡咯基,3-N,N-二乙基氨基四氢吡咯基,4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基。5) piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diisopropylaminopiperidinyl, 4 -Hydroxypiperidyl, morpholinyl, 3,5-dimethylmorpholinyl, 3-N,N-dimethylaminotetrahydropyrrolyl, 3-N,N-diethylaminotetrahydropyrrolyl , 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-(2-N,N-diethylaminoethyl) Piperazinyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl.
在一些实施方案中,R2选自:In some embodiments, R 2 is selected from:
1)其中A1,A2,A3,A4,A5各自独立地选自:1) wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,(1) Hydrogen, Fluorine, Chlorine,
(2)甲硫基,乙硫基,异丙硫基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,叔丁磺酰基,二甲氨基磺酰基,甲磺酰氨基,甲氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,环丁基氨基羰基,甲氨基羰基,二甲氨基羰基,异丙氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基,(2) methylthio, ethylthio, isopropylthio, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethanesulfonyl, isopropylsulfonyl, tert-butanesulfonyl, dimethylaminosulfonyl Acyl, methanesulfonylamino, methoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, cyclobutylaminocarbonyl, methylaminocarbonyl, dimethylaminocarbonyl, isopropylaminocarbonyl, Dimethylphosphinoyl, Diethylphosphinoyl, Diisopropylphosphinoyl,
2) 2)
其中,Y为NH,S或O原子,where Y is an NH, S or O atom,
A6,A7,A8,A9,A10,A11各自独立地选自:A 6 , A 7 , A 8 , A 9 , A 10 , A 11 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环戊基氨基羰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, Propylaminocarbonyl, isopropylaminocarbonyl, cyclopentylaminocarbonyl;
3) 3)
其中A12选自:where A 12 is selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丁基氨基羰基,甲基亚磺酰基,甲基磺酰基,乙基磺酰基,异丙基磺酰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropyl Aminocarbonyl, cyclobutylaminocarbonyl, methylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl;
Y2,Y3,Y4选自以下组合:Y 2 , Y 3 , Y 4 are selected from the following combinations:
Y2为N,Y3为N-A13,Y4为CH或N;Y 2 is N, Y 3 is NA 13 , and Y 4 is CH or N;
Y2为O或S,Y3为C-A13,Y4为N;和Y 2 is O or S, Y 3 is CA 13 , and Y 4 is N; and
Y2为C,Y3为N-A13,Y4为O或S;Y 2 is C, Y 3 is NA 13 , and Y 4 is O or S;
Y2为C,Y3为N-A13,Y4为N;Y 2 is C, Y 3 is NA 13 , and Y 4 is N;
其中A13为氢,C1-C6烷基,C2-C6烯基,C2-C6炔基,C3-C6环烷基。wherein A 13 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl.
在一些实施方案中,所述药学上可接受的盐为无机酸盐或有机酸盐,其中,所述无机酸盐为盐酸盐、氢溴酸盐、氢碘酸盐、硝酸盐、碳酸氢盐和碳酸盐、硫酸盐或磷酸盐,所述有机酸盐为甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、抗坏血酸盐、α-酮戊二酸盐、三氟乙酸盐、α-甘油磷酸盐、烷基磺酸盐或芳基磺酸盐;优选地,所述烷基磺酸盐为甲基磺酸盐或乙基磺酸盐;所述芳基磺酸盐为苯磺酸盐或对甲苯磺酸盐。In some embodiments, the pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt, wherein the inorganic acid salt is hydrochloride, hydrobromide, hydroiodide, nitrate, bicarbonate Salts and carbonates, sulfates or phosphates, the organic acid salts being formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid salt, citrate, ascorbate, alpha-ketoglutarate, trifluoroacetate, alpha-glycerophosphate, alkylsulfonate or arylsulfonate; preferably, the alkylsulfonate The salt is methanesulfonate or ethylsulfonate; the arylsulfonate is benzenesulfonate or p-toluenesulfonate.
第二方面,本发明提供了一种具有式V结构化合物、其立体异构体、其前药、或者其药学上可接受的盐或药学上可接受的溶剂合物:In the second aspect, the present invention provides a compound having the structure of formula V, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate:
其中:W为氧代,硫代,或氢;Wherein: W is oxo, thio, or hydrogen;
n=0,或1;n=0, or 1;
R3,R4,R5各自独立地选自:R 3 , R 4 , R 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基;(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy;
R6选自:R 6 is selected from:
(1)氢,C1-C6烷基,乙酰基,丙酰基,正丁酰基,异丁酰基,(1) Hydrogen, C1-C6 alkyl, acetyl, propionyl, n-butyryl, isobutyryl,
(2)氨基乙酰基,2-N,N-二甲基乙酰基,2-N,N-二乙基乙酰基,2-N,N-二异丙基乙酰基,哌啶基乙酰基,4-羟基哌啶基乙酰基,4-N,N-二甲基氨基哌啶基乙酰基,4-N,N-二乙基氨基哌啶基乙酰基,四氢吡咯基乙酰基,3-N,N-二甲基氨基四氢吡咯基乙酰基,3-N,N-二乙基氨基四氢吡咯基乙酰基,4-甲基哌嗪基乙酰基,4-乙基哌嗪基乙酰基,4-乙酰基哌嗪基乙酰基,4-叔丁氧羰基哌嗪基乙酰基,4-(2-羟基乙基)哌嗪基乙酰基,4-(2-氰基乙基)哌嗪基乙酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基乙酰基,4-(2-N,N-二乙基氨基乙基)哌嗪基乙酰基,4-(3-羟基丙基)哌嗪基乙酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基乙酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基乙酰基,吗啉基乙酰基,3,5-二甲基吗啉基乙酰基,4-(4-甲基-哌嗪-1-基)哌啶基乙酰基,4-(4-乙基-1-哌嗪基)哌啶基乙酰基,4-(4-乙酰基-1-哌嗪基)哌啶基乙酰基,4-(N-甲基-4-哌啶基)哌嗪基乙酰基;(2) Aminoacetyl, 2-N,N-dimethylacetyl, 2-N,N-diethylacetyl, 2-N,N-diisopropylacetyl, piperidinylacetyl, 4-Hydroxypiperidinylacetyl, 4-N,N-dimethylaminopiperidinylacetyl, 4-N,N-diethylaminopiperidinylacetyl, tetrahydropyrrolylacetyl, 3- N,N-Dimethylaminotetrahydropyrrolylacetyl, 3-N,N-diethylaminotetrahydropyrrolylacetyl, 4-methylpiperazinylacetyl, 4-ethylpiperazinylacetyl base, 4-acetylpiperazinylacetyl, 4-tert-butoxycarbonylpiperazinylacetyl, 4-(2-hydroxyethyl)piperazinylacetyl, 4-(2-cyanoethyl)piperyl Azinylacetyl, 4-(2-N,N-dimethylaminoethyl)piperazinylacetyl, 4-(2-N,N-diethylaminoethyl)piperazinylacetyl, 4 -(3-Hydroxypropyl)piperazinylacetyl, 4-(3-N,N-dimethylaminopropyl)piperazinylacetyl, 4-(3-N,N-diethylaminopropyl yl)piperazinylacetyl, morpholinylacetyl, 3,5-dimethylmorpholinylacetyl, 4-(4-methyl-piperazin-1-yl)piperidinylacetyl, 4- (4-Ethyl-1-piperazinyl)piperidinylacetyl, 4-(4-acetyl-1-piperazinyl)piperidinylacetyl, 4-(N-methyl-4-piperidine base) piperazinyl acetyl;
A,X,R2与上述技术方案中定义相同。A, X, R 2 are the same as defined in the above technical solutions.
在一些实施方案中,W为氧代。In some embodiments, W is oxo.
在一些实施方案中,n=1。In some embodiments, n=1.
在一些实施方案中,n=0。In some embodiments, n=0.
在一些实施方案中,R3,R4,R5各自独立地选自:In some embodiments, R 3 , R 4 , R 5 are each independently selected from:
(1)氢,氟,氯,溴,碘;(1) hydrogen, fluorine, chlorine, bromine, iodine;
(2)C1-C6烷基,C1-C6烷氧基。(2) C1-C6 alkyl, C1-C6 alkoxy.
在一些实施方案中,R6选自:In some embodiments, R 6 is selected from:
(1)氢,C1-C6烷基,乙酰基,丙酰基,(1) Hydrogen, C1-C6 alkyl, acetyl, propionyl,
(2)氨基乙酰基,2-N,N-二甲基乙酰基,2-N,N-二乙基乙酰基,2-N,N-二异丙基乙酰基,哌啶基乙酰基,4-羟基哌啶基乙酰基,4-N,N-二甲基氨基哌啶基乙酰基,4-N,N-二乙基氨基哌啶基乙酰基,四氢吡咯基乙酰基,4-乙酰基哌嗪基乙酰基,4-叔丁氧羰基哌嗪基乙酰基,4-(2-羟基乙基)哌嗪基乙酰基,4-(2-氰基乙基)哌嗪基乙酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基乙酰基,4-(2-N,N-二乙基氨基乙基)哌嗪基乙酰基,吗啉基乙酰基,3,5-二甲基吗啉基乙酰基,4-(4-甲基-哌嗪-1-基)哌啶基乙酰基,4-(4-乙基-1-哌嗪基)哌啶基乙酰基。(2) Aminoacetyl, 2-N,N-dimethylacetyl, 2-N,N-diethylacetyl, 2-N,N-diisopropylacetyl, piperidinylacetyl, 4-Hydroxypiperidinylacetyl, 4-N,N-dimethylaminopiperidinylacetyl, 4-N,N-diethylaminopiperidinylacetyl, tetrahydropyrrolylacetyl, 4- Acetylpiperazinylacetyl, 4-tert-butoxycarbonylpiperazinylacetyl, 4-(2-hydroxyethyl)piperazinylacetyl, 4-(2-cyanoethyl)piperazinylacetyl , 4-(2-N,N-dimethylaminoethyl)piperazinylacetyl, 4-(2-N,N-diethylaminoethyl)piperazinylacetyl, morpholinoacetyl , 3,5-dimethylmorpholinylacetyl, 4-(4-methyl-piperazin-1-yl)piperidinylacetyl, 4-(4-ethyl-1-piperazinyl)piperyl pyridylacetyl.
在一些实施方案中,所述药学上可接受的盐为无机酸盐或有机酸盐,其中,所述无机酸盐为盐酸盐、氢溴酸盐、氢碘酸盐、硝酸盐、碳酸氢盐和碳酸盐、硫酸盐或磷酸盐,所述有机酸盐为甲酸盐、乙酸盐、丙酸盐、苯甲酸盐、马来酸盐、富马酸盐、琥珀酸盐、酒石酸盐、柠檬酸盐、抗坏血酸盐、α-酮戊二酸盐、三氟乙酸盐、α-甘油磷酸盐、烷基磺酸盐或芳基磺酸盐;优选地,所述烷基磺酸盐为甲基磺酸盐或乙基磺酸盐;所述芳基磺酸盐为苯磺酸盐或对甲苯磺酸盐。In some embodiments, the pharmaceutically acceptable salt is an inorganic acid salt or an organic acid salt, wherein the inorganic acid salt is hydrochloride, hydrobromide, hydroiodide, nitrate, bicarbonate Salts and carbonates, sulfates or phosphates, the organic acid salts being formate, acetate, propionate, benzoate, maleate, fumarate, succinate, tartaric acid salt, citrate, ascorbate, alpha-ketoglutarate, trifluoroacetate, alpha-glycerophosphate, alkylsulfonate or arylsulfonate; preferably, the alkylsulfonate The salt is methanesulfonate or ethylsulfonate; the arylsulfonate is benzenesulfonate or p-toluenesulfonate.
第三方面,本发明提供了一种下面通式IA表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a third aspect, the present invention provides a compound represented by the following general formula IA, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自:其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基,(3) C1-C6 alkoxy,
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl,
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(6)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,或(6) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl, or
(7)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基。(7) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered or six-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,(2) methyl,
(3)甲氧基,(3) Methoxy,
(4)N-甲基-4-哌啶基,(4) N-methyl-4-piperidinyl,
(5)4-甲基哌嗪基,(5) 4-methylpiperazinyl,
(6)4-(4-甲基哌嗪基)哌啶基,(6) 4-(4-methylpiperazinyl) piperidinyl,
(7)4-(四氢吡咯-1-基)哌啶基,或(7) 4-(tetrahydropyrrol-1-yl)piperidinyl, or
(8)Z2与Z3或Z3与Z4形成 (8) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
1)其中Z1和Z5二者之一为氢,另一为甲氧基;1) Wherein one of Z 1 and Z 5 is hydrogen, and the other is methoxy;
Z2和Z4二者之一为氢,另一为甲基;One of Z 2 and Z 4 is hydrogen, and the other is methyl;
Z3选自:N-甲基-4-哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,或Z 3 is selected from: N-methyl-4-piperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl) piperidinyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:(1)氢,(2)甲磺酰基。In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from: (1) hydrogen, (2) methanesulfonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为甲磺酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is methanesulfonyl; A 2 , A 3 and A 4 are all hydrogen.
第四方面,本发明提供了一种下面通式IB表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a fourth aspect, the present invention provides a compound represented by the following general formula IB, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,2-氧代-哌嗪-4-基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl, 2-oxo-piperazin-4-yl,
(5)吗啉基,3,5-二甲基吗啉基,硫啡啉基,(5) morpholinyl, 3,5-dimethylmorpholinyl, thiophanolinyl,
(6)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(6) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclopentylaminosulfonyl, piperidine-1 -ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-diethylaminopiperidin-1 -ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4- Ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl) yl)piperazinyl-1-sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl ) piperazinyl-1-sulfonyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1- Sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylsulfonyl Acyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(7)4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-(2-羟基乙基)哌嗪3-N,N-二乙基氨基四氢吡咯基-1-羰基,基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,3,5-二甲基吗啉基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(7) 4-(4-Methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, Cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1-carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4 -N,N-Diethylaminopiperidinyl-1-carbonyl, tetrahydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N -Dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-(2-hydroxyethyl)piperazine 3-N,N- Diethylaminotetrahydropyrrolyl-1-carbonyl, yl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3-N,N-dimethylaminopropyl yl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1-carbonyl, hydroxycarbonyl, aminocarbonyl, methylamino Carbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl , isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(8)吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,或(8) pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalo-substituted phenylmethoxy, or
(9)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(9) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
3)其中Z2,Z3,Z4,Z5与上述2)中定义相同;4)其中Z1,Z3,Z4,Z5与上述2)中定义相同;3) Wherein Z 2 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2); 4) Wherein Z 1 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2);
R2选自:其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
1)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:1) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基,(3) C1-C6 alkoxy,
(4)N-甲基-4-哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,(4) N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, piperidine base, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diisopropylaminopiperidinyl,
(5)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,2-氧代-哌嗪-4-基(5) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 2-oxo-piperazin-4-yl
(6)吗啉基,3,5-二甲基吗啉基,(6) morpholinyl, 3,5-dimethylmorpholinyl,
(7)4-羟基哌啶-1-基磺酰基,4-甲基哌嗪-1-基磺酰基,羟基磺酰基,氨基磺酰基,甲氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-乙基哌嗪基-1-磺酰基,(7) 4-Hydroxypiperidin-1-ylsulfonyl, 4-methylpiperazin-1-ylsulfonyl, hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl Acyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidine- 1-ylsulfonyl, 4-N,N-diethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl- 1-sulfonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-sulfonyl, 4-ethylpiperazinyl-1-sulfonyl,
(8)4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-甲基哌嗪-1-基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,(8) 4-(4-Methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, Piperidinyl-1-carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl -1-Carbonyl, tetrahydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1- Carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N, N-diethylaminopropyl) piperazinyl-1-carbonyl, morpholinyl-1-carbonyl,
(9)吡啶-2-基甲氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,或(9) pyridin-2-ylmethoxy, pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenyl methoxy, or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
2)其中Z2,Z3,Z4,Z5与上述2)中定义相同;2) Wherein Z 2 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2);
3)其中Z1,Z3,Z4,Z5与上述2)中定义相同。3) Wherein Z 1 , Z 3 , Z 4 , Z 5 are the same as defined in the above 2).
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
1)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:1) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,(2) methyl,
(3)甲氧基、乙氧基、异丙氧基,(3) Methoxy, ethoxy, isopropoxy,
(4)N-甲基-4-哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-二甲氨基-哌啶基,(4) N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl , 4-Dimethylamino-piperidinyl,
(5)4-甲基哌嗪基,4-叔丁氧羰基哌嗪基,(5) 4-methylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl,
(6)吗啉基,(6) Morpholinyl,
(7)4-羟基哌啶-1-基磺酰基,4-甲基哌嗪-1-基磺酰基,(7) 4-hydroxypiperidin-1-ylsulfonyl, 4-methylpiperazin-1-ylsulfonyl,
(8)4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-甲基哌嗪-1-基羰基,(8) 4-(4-Methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl,
(9)吡啶-2-基甲氧基,(9) pyridin-2-ylmethoxy,
(10)2-二甲氨基乙酰氨基, (10) 2-dimethylaminoacetamido,
(11)–F,(11)–F,
(12)Z2与Z3或Z3与Z4形成 (12) Z 2 and Z 3 or Z 3 and Z 4 form
2)其中Z2,Z3,Z4,Z5各自独立地选自:吗啉基,4-甲基哌嗪基,4-羟基哌啶基;2) wherein Z 2 , Z 3 , Z 4 , and Z 5 are each independently selected from: morpholinyl, 4-methylpiperazinyl, and 4-hydroxypiperidinyl;
3)其中Z1,Z3,Z4,Z5各自独立地选自:吗啉基,4-羟基哌啶基。3) wherein Z 1 , Z 3 , Z 4 , and Z 5 are each independently selected from: morpholinyl, 4-hydroxypiperidinyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
1)其中Z1和Z5二者之一为氢,另一选自:甲氧基、乙氧基、异丙氧基;1) Wherein one of Z 1 and Z 5 is hydrogen, and the other is selected from: methoxy, ethoxy, isopropoxy;
Z2和Z4二者之一为氢,另一为甲基,2-二甲氨基乙酰氨基, One of Z 2 and Z 4 is hydrogen, the other is methyl, 2-dimethylaminoacetamido,
Z3选自:N-甲基-4-哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-甲基哌嗪基,4-叔丁氧羰基哌嗪基,吗啉基,4-羟基哌啶-1-基磺酰基,4-甲基哌嗪-1-基磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-甲基哌嗪-1-基羰基,吡啶-2-基甲氧基,4-二甲氨基-哌啶基,-F;或Z 3 is selected from: N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidyl Imidyl, 4-methylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, morpholinyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-(4-Methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-methylpiperazin-1-ylcarbonyl, pyridin-2-ylmethoxy, 4-dimethylamino- piperidinyl, -F; or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
2)其中Z3选自:吗啉基,4-甲基哌嗪基,4-羟基哌啶基;Z1、Z2和Z4都为氢;2) wherein Z 3 is selected from: morpholinyl, 4-methylpiperazinyl, 4-hydroxypiperidinyl; Z 1 , Z 2 and Z 4 are all hydrogen;
3)其中Z3选自:吗啉基,4-羟基哌啶基;Z1、Z2和Z4都为氢。3) wherein Z 3 is selected from: morpholinyl, 4-hydroxypiperidinyl; Z 1 , Z 2 and Z 4 are all hydrogen.
在一些实施方案中,R2选自:In some embodiments, R2 is selected from:
其中A1,A2,A3,A4,A5各自独立地选自:(1)氢,(2)异丙基磺酰基。 wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from: (1) hydrogen, (2) isopropylsulfonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为异丙基磺酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, the other is isopropylsulfonyl; A 2 , A 3 and A 4 are all hydrogen.
第五方面,本发明提供了一种下面通式IO表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a fifth aspect, the present invention provides a compound represented by the following general formula IO, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diiso propylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-iso Propylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonyl Piperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4 -(4-(3-Hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4 -(2-N,N-Diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethyl ylaminotetrahydropyrrolyl)piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,叔丁磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) Methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, tert-butanesulfonyl , methanesulfonylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethyl Aminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphine Acyl.
在一些实施方案中,R1选自其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4--二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4--dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl Isopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4- Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonyl) acylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-Hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-( 4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl , 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-di Methylaminotetrahydropyrrolyl)piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基或(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl or
(5)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(5) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents may be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地任选自: Wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基(2) C1-C6 alkoxy
(3)4-(4-甲基哌嗪-1-基)哌啶基,4-甲基哌嗪基,4-二甲氨基-哌啶基,(3) 4-(4-methylpiperazin-1-yl) piperidinyl, 4-methylpiperazinyl, 4-dimethylamino-piperidinyl,
(4)Z2与Z3可以形成含氮的取代或未取代的五元环 (4) Z 2 and Z 3 can form a nitrogen-containing substituted or unsubstituted five-membered ring
在一些实施方案中,R1选自:其中,In some embodiments, R1 is selected from: in,
Z1为甲氧基,且Z3选自:4-二甲氨基-哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,其余为氢;或Z 1 is methoxy, and Z 3 is selected from: 4-dimethylamino-piperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, and the rest are hydrogen; or
Z3与Z4形成且Z1为甲氧基,其余为氢。Z 3 is formed with Z 4 And Z 1 is methoxy, and the rest are hydrogen.
在一些实施方案中,R2选自其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢;(2)叔丁磺酰基。(1) hydrogen; (2) tert-butanesulfonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为叔丁磺酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, the other is tert-butanesulfonyl; A 2 , A 3 and A 4 are all hydrogen.
第六方面,本发明提供了一种下面通式IC表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a sixth aspect, the present invention provides a compound represented by the following general formula IC, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,或(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl, or
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自:1) R2 is selected from: 1)
其中,Y为NH,S或O原子,where Y is an NH, S or O atom,
A6,A7,A8,A9,A10,A11各自独立地选自:A 6 , A 7 , A 8 , A 9 , A 10 , A 11 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, Propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl;
2) 2)
其中A12选自:where A 12 is selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,甲基亚磺酰基,乙基亚磺酰基,异丙基亚磺酰基,甲基磺酰基,乙基磺酰基,异丙基磺酰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, Propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl , ethylsulfonyl, isopropylsulfonyl;
Y2,Y3,Y4为以下组合:Y 2 , Y 3 , Y 4 are the following combinations:
Y2为C,Y3为N-A13,Y4为N,或Y 2 is C, Y 3 is NA 13 , Y 4 is N, or
Y2为N,Y3为N-A13,Y4为CH或N;Y 2 is N, Y 3 is NA 13 , and Y 4 is CH or N;
其中A13为氢,C1-C6烷基。wherein A 13 is hydrogen, C1-C6 alkyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)4-羟基哌啶基,哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,(3) 4-Hydroxypiperidinyl, piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidyl pyridyl, 4-N,N-diisopropylaminopiperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,或(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl, or
(6)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(6) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲氧基,(2) Methoxy,
(3)4-羟基哌啶基,(3) 4-hydroxypiperidinyl,
(4)4-甲基哌嗪基,(4) 4-methylpiperazinyl,
(5)4-(4-甲基哌嗪基)哌啶基,或(5) 4-(4-Methylpiperazinyl)piperidinyl, or
(6)Z2与Z3或Z3与Z4形成 (6) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一为甲氧基,Z4为氢; Wherein one of Z 1 and Z 5 is hydrogen, the other is methoxy, and Z 4 is hydrogen;
Z3选自:4-羟基哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,或Z 3 is selected from: 4-hydroxypiperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, or
Z2与Z3形成 Z 2 is formed with Z 3
在一些实施方案中,R2选自: In some embodiments, R2 is selected from:
其中A12选自:where A 12 is selected from:
(1)氢,甲基,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) Hydrogen, methyl, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,甲基亚磺酰基,乙基亚磺酰基,异丙基亚磺酰基,甲基磺酰基,乙基磺酰基,异丙基磺酰基;(2) Methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, Propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl , ethylsulfonyl, isopropylsulfonyl;
Y2,Y3,Y4为以下组合:Y 2 , Y 3 , Y 4 are the following combinations:
Y2为C,Y3为N-A13,Y4为N,或Y 2 is C, Y 3 is NA 13 , Y 4 is N, or
Y2为N,Y3为N-A13,Y4为CH或N;Y 2 is N, Y 3 is NA 13 , and Y 4 is CH or N;
其中A13为氢,C1-C6烷基。wherein A 13 is hydrogen, C1-C6 alkyl.
在一些实施方案中,R2选自: In some embodiments, R2 is selected from:
其中A12选自:where A 12 is selected from:
(1)氢,甲基,(1) hydrogen, methyl,
(2)异丙基磺酰基;(2) isopropylsulfonyl;
Y2,Y3,Y4为以下组合:Y 2 , Y 3 , Y 4 are the following combinations:
Y2为C,Y3为N-A13,Y4为N,Y 2 is C, Y 3 is NA 13 , Y 4 is N,
其中A13为氢,C1-C6烷基。wherein A 13 is hydrogen, C1-C6 alkyl.
在一些实施方案中,R2选自: In some embodiments, R2 is selected from:
其中A12选自异丙基磺酰基;wherein A 12 is selected from isopropylsulfonyl;
Y2,Y3,Y4为以下组合:Y2为C,Y3为N-A13,Y4为N,其中A13为甲基。Y 2 , Y 3 , Y 4 are the following combinations: Y 2 is C, Y 3 is NA 13 , Y 4 is N, and A 13 is methyl.
第七方面,本发明提供了一种下面通式ID表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a seventh aspect, the present invention provides a compound represented by the following general formula ID, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-Hydroxypiperidinyl-1-carbonyl, 4-N,N-Dimethylaminopiperidinyl-1-carbonyl, 4-N,N-Diethylaminopiperidinyl-1-carbonyl, Tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as those of Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基,(3) C1-C6 alkoxy,
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(6)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基或(6) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl or
(7)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(7) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,(2) methyl,
(3)甲氧基、异丙氧基,(3) Methoxy, isopropoxy,
(4)N-甲基-4-哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,(4) N-methyl-4-piperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl,
(5)4-甲基哌嗪基,或(5) 4-methylpiperazinyl, or
(6)Z2与Z3或Z3与Z4形成 (6) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z2和Z4二者之一为氢,另一为甲基, One of Z 2 and Z 4 is hydrogen, the other is methyl,
Z1和Z5二者之一为氢,另一选自:甲氧基、异丙氧基,One of Z 1 and Z 5 is hydrogen, and the other is selected from: methoxy, isopropoxy,
Z3选自:N-甲基-4-哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,或Z 3 is selected from: N-methyl-4-piperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl) piperidinyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢;(2)甲氧基羰基。(1) Hydrogen; (2) Methoxycarbonyl.
在一些实施方案中,R2选自:其中A2和A4二者之一为氢,另一为甲氧基羰基;A1,A3,A5都为氢。In some embodiments, R2 is selected from: One of A 2 and A 4 is hydrogen, and the other is methoxycarbonyl; A 1 , A 3 and A 5 are all hydrogen.
第八方面,本发明提供了一种下面通式IE表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In an eighth aspect, the present invention provides a compound represented by the following general formula IE, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,甲亚磺酰基,乙亚磺酰基,甲磺酰基,乙磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基。(2) Methylthio, ethylthio, methanesulfinyl, ethylsulfinyl, methanesulfonyl, ethanesulfonyl, methanesulfonylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso Propoxycarbonyl, n-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基,(3) C1-C6 alkoxy,
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl,
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(6)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基。(6) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl.
在一些实施方案中,R1选自其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,甲氧基,乙氧基,异丙氧基,(2) methyl, methoxy, ethoxy, isopropoxy,
(3)N-甲基-4-哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,(3) N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl ,
(4)4-甲基哌嗪基。(4) 4-methylpiperazinyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一选自:甲氧基、乙氧基、异丙氧基; Wherein one of Z 1 and Z 5 is hydrogen, and the other is selected from: methoxy, ethoxy, isopropoxy;
Z2和Z4二者之一为氢,另一为甲基;One of Z 2 and Z 4 is hydrogen, and the other is methyl;
Z3选自:N-甲基-4-哌啶基,4-羟基哌啶基、4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基。Z 3 is selected from: N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl) piperidinyl, 4-(tetrakis Hydropyrrol-1-yl)piperidinyl.
在一些实施方案中,R2选自其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)甲氧基羰基。(1) Hydrogen, (2) Methoxycarbonyl.
在一些实施方案中,R2选自其中A1和A5二者之一为氢,另一为甲氧基羰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from One of A 1 and A 5 is hydrogen, and the other is methoxycarbonyl; A 2 , A 3 and A 4 are all hydrogen.
第九方面,本发明提供了一种下面通式IF表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a ninth aspect, the present invention provides a compound represented by the following general formula IF, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(N-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as those of Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基(3) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,或(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl, 4-(3 -N,N-Dimethylaminotetrahydropyrrolyl)piperidinyl, or
(5)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(5) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲氧基,(2) Methoxy,
(3)4-甲基哌嗪基,(3) 4-methylpiperazinyl,
(4)4-(4-甲基哌嗪基)哌啶基,或(4) 4-(4-Methylpiperazinyl)piperidinyl, or
(5)Z2与Z3或Z3与Z4形成 (5) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一为甲氧基;Z4为氢; Wherein one of Z 1 and Z 5 is hydrogen, the other is methoxy; Z 4 is hydrogen;
Z3选自:4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,或Z 3 is selected from: 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidyl, or
Z2与Z3形成 Z 2 forms with Z 3
在一些实施方案中,R2选自其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)氟,(3)甲氨基羰基。(1) Hydrogen, (2) Fluorine, (3) Methylaminocarbonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为选自:氟,甲氨基羰基;且A2和A4二者之一为氢,另一为选自:氟,甲氨基羰基;A3为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is selected from: fluorine, methylaminocarbonyl; and one of A 2 and A 4 is hydrogen, and the other is selected from: fluorine, methylaminocarbonyl; A 3 is hydrogen.
在一些实施方案中,R2选自:其中,A1和A5二者之一为氢,另一为甲氨基羰基;且A2和A4二者之一为氢,另一为氟;A3为氢。In some embodiments, R2 is selected from: Wherein, one of A 1 and A 5 is hydrogen, and the other is methylaminocarbonyl; and one of A 2 and A 4 is hydrogen, and the other is fluorine; A 3 is hydrogen.
第十方面,本发明提供了一种下面通式IG表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,Tenth aspect, the present invention provides a compound represented by the following general formula IG, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) propylaminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-di Ethylaminopropyl, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6 cycloalkyl, 4 -N,N-Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-iso Propyl-4-piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-( N-methyl-4-piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自:其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,甲亚磺酰基,乙亚磺酰基,甲磺酰基,乙磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基。(2) Methylthio, ethylthio, methanesulfinyl, ethylsulfinyl, methanesulfonyl, ethanesulfonyl, methanesulfonylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso Propoxycarbonyl, n-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基,(3) C1-C6 alkoxy,
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(6)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(6) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,或(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl, or
(8)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(8) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,甲氧基,(2) methyl, methoxy,
(3)N-甲基-4-哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,(3) N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl ,
(4)氨基磺酰基,或(4) Sulfamoyl, or
(5)Z2与Z3或Z3与Z4形成 (5) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一为甲氧基; Wherein one of Z 1 and Z 5 is hydrogen, and the other is methoxy;
Z2和Z4二者之一为氢,另一为甲基;One of Z 2 and Z 4 is hydrogen, and the other is methyl;
Z3选自:N-甲基-4-哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,氨基磺酰基,或Z 3 is selected from: N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidyl pyridyl, sulfamoyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)甲磺酰氨基。(1) Hydrogen, (2) Methanesulfonylamino.
在一些实施方案中,R2选自:其中A2和A4二者之一为氢,另一为甲磺酰氨基;A1,A3,A5都为氢。In some embodiments, R2 is selected from: One of A 2 and A 4 is hydrogen, the other is methanesulfonylamino; A 1 , A 3 and A 5 are all hydrogen.
第十一方面,本发明提供了一种下面通式IH表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,Eleventh aspect, the present invention provides a compound represented by the following general formula IH, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)丙基氨基乙基,2-吗啉基乙基,2-(4-4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) Propylaminoethyl, 2-morpholinoethyl, 2-(4-4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N -Diethylaminopropyl, 3-N,N-diisopropylaminopropyl, 3-morpholinopropyl, 3-(4-methylpiperazinyl)propyl, C3-C6 cycloalkyl , 4-N,N-dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N -Isopropyl-4-piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1 -(N-methyl-4-piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as those of Z 1 ;
R2选自:2)其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from: 2) wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,甲亚磺酰基,乙亚磺酰基,甲磺酰基,乙磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基。(2) Methylthio, ethylthio, methanesulfinyl, ethylsulfinyl, methanesulfonyl, ethanesulfonyl, methanesulfonylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso Propoxycarbonyl, n-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(4)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(4) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(5)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(5) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(6)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,或(6) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl, or
(7)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基。(7) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five- or six-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲氧基,(2) Methoxy,
(3)N-甲基-4-哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,(3) N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl ,
(4)4-甲基哌嗪基,(4) 4-methylpiperazinyl,
(5)氨基磺酰基,或(5) Sulfamoyl, or
(6)Z2与Z3或Z3与Z4形成 (6) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一为甲氧基;Z4为氢; Wherein one of Z 1 and Z 5 is hydrogen, the other is methoxy; Z 4 is hydrogen;
Z3选自:N-甲基-4-哌啶基,4-羟基哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,氨基磺酰基,或Z 3 is selected from: N-methyl-4-piperidinyl, 4-hydroxypiperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl) piperidinyl, 4-(tetrakis Hydropyrrol-1-yl)piperidinyl, aminosulfonyl, or
Z2与Z3形成 Z 2 is formed with Z 3
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲磺酰氨基。(2) Methanesulfonamido.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为甲磺酰氨基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is methanesulfonylamino; A 2 , A 3 and A 4 are all hydrogen.
第十二方面,本发明提供了一种下面通式II表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a twelfth aspect, the present invention provides a compound represented by the following general formula II, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) propylaminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-di Ethylaminopropyl, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6 cycloalkyl, 4 -N,N-Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-iso Propyl-4-piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-( N-methyl-4-piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido;
R2选自:其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基,(3) C1-C6 alkoxy,
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(6)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基。(6) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,甲氧基、乙氧基、异丙氧基;(2) methyl, methoxy, ethoxy, isopropoxy;
(3)N-甲基-4-哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-羟基哌啶基;(3) N-methyl-4-piperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl, 4-hydroxypiperidinyl ;
(4)4-甲基哌嗪基。(4) 4-methylpiperazinyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一选自:甲氧基、乙氧基、异丙氧基; Wherein one of Z 1 and Z 5 is hydrogen, and the other is selected from: methoxy, ethoxy, isopropoxy;
Z2和Z4二者之一为氢,另一为甲基;One of Z 2 and Z 4 is hydrogen, and the other is methyl;
Z3选自:N-甲基-4-哌啶基,4-甲基哌嗪基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基。Z 3 is selected from: N-methyl-4-piperidinyl, 4-methylpiperazinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl) piperidinyl, 4-(tetrakis Hydropyrrol-1-yl)piperidinyl.
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:(1)氢;(2)甲氨基羰基。In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 and A 5 are each independently selected from: (1) hydrogen; (2) methylaminocarbonyl.
在一些实施方案中,R2选自其中A1和A5二者之一为氢,另一为甲氨基羰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from One of A 1 and A 5 is hydrogen, the other is methylaminocarbonyl; A 2 , A 3 and A 4 are all hydrogen.
第十三方面,本发明提供了一种下面通式IPQ表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a thirteenth aspect, the present invention provides a compound represented by the following general formula IPQ, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diiso propylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-iso Propylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonyl Piperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4 -(4-(3-Hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4 -(2-N,N-Diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethyl ylaminotetrahydropyrrolyl)piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,叔丁磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,二甲氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) Methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, tert-butanesulfonyl , methanesulfonylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethyl Aminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diethylaminocarbonyl Isopropylphosphinoyl.
在一些实施方案中,R1选自其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4--二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4--dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl Isopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4- Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonyl) acylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-Hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-( 4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl , 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-di Methylaminotetrahydropyrrolyl)piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基或(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl or
(5)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(5) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents may be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:其中Z1,Z2,Z3,Z4,Z5各自独立地任选自:In some embodiments, R1 is selected from: Wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)4-(4-甲基哌嗪基)哌啶基,4-甲基哌嗪基,4-二甲氨基-哌啶基。(3) 4-(4-Methylpiperazinyl)piperidinyl, 4-methylpiperazinyl, 4-dimethylamino-piperidinyl.
在一些实施方案中,R1选自:其中,In some embodiments, R1 is selected from: in,
Z1为甲氧基,且Z3选自:4-二甲氨基-哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,其余为氢;或Z 1 is methoxy, and Z 3 is selected from: 4-dimethylamino-piperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, and the rest are hydrogen; or
Z3与Z4形成且Z1为甲氧基,其余为氢。Z 3 is formed with Z 4 And Z 1 is methoxy, and the rest are hydrogen.
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地任选自:In some embodiments, R2 is selected from: Wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)异丙氨基羰基,二甲氨基羰基。(1) hydrogen, (2) isopropylaminocarbonyl, dimethylaminocarbonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为异丙氨基羰基或二甲氨基羰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is isopropylaminocarbonyl or dimethylaminocarbonyl; A 2 , A 3 and A 4 are all hydrogen.
第十四方面,本发明提供了一种下面通式IJ表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a fourteenth aspect, the present invention provides a compound represented by the following general formula IJ, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) propylaminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-di Ethylaminopropyl, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6 cycloalkyl, 4 -N,N-Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-iso Propyl-4-piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-( N-methyl-4-piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(N-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(N-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自:其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基,(3) C1-C6 alkoxy,
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl,
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(6)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,或(6) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl, or
(7)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(7) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,甲氧基,(2) methyl, methoxy,
(3)N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,(3) N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrole- 1-yl) piperidinyl,
(4)4-甲基哌嗪基,或(4) 4-methylpiperazinyl, or
(5)Z2与Z3或Z3与Z4形成 (5) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:其中Z1和Z5二者之一为氢,另一为甲氧基,Z2和Z4二者之一为氢,另一为甲基,In some embodiments, R1 is selected from: One of Z 1 and Z 5 is hydrogen, the other is methoxy, one of Z 2 and Z 4 is hydrogen, and the other is methyl,
Z3选自:N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,或Z 3 is selected from: N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidine pyridinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)异丙亚磺酰基。(1) hydrogen, (2) isopropylsulfinyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为异丙亚磺酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is isopropylsulfinyl; A 2 , A 3 and A 4 are all hydrogen.
第十五方面,本发明提供了一种下面通式IK表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a fifteenth aspect, the present invention provides a compound represented by the following general formula IK, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自:其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基(3) C1-C6 alkoxy
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(6)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,或(6) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl, or
(7)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基。(7) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered or six-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,甲氧基,(2) methyl, methoxy,
(3)4-甲基哌嗪基,(3) 4-methylpiperazinyl,
(4)N-甲基-4-哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-N,N-二甲基氨基哌啶基,或(4) N-methyl-4-piperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl, 4-N,N- Dimethylaminopiperidinyl, or
(5)Z2与Z3或Z3与Z4形成 (5) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自其中Z2和Z4二者之一为氢,另一为甲基,Z1和Z5二者之一为氢,另一为甲氧基,In some embodiments, R1 is selected from Wherein one of Z 2 and Z 4 is hydrogen, the other is methyl, one of Z 1 and Z 5 is hydrogen, and the other is methoxy,
Z3选自:N-甲基-4-哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-N,N-二甲基氨基哌啶基,或Z 3 is selected from: N-methyl-4-piperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl) piperidinyl, 4-N,N-dimethylaminopiperidinyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)二甲基次膦酰基。(1) Hydrogen, (2) Dimethylphosphinoyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为二甲基次膦酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is dimethylphosphinoyl; A 2 , A 3 and A 4 are all hydrogen.
第十六方面,本发明提供了一种下面通式IRS表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a sixteenth aspect, the present invention provides a compound represented by the following general formula IRS, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,4-(四氢吡咯-1-基)哌啶基(3) piperidinyl, N-methyl-4-piperidinyl, 4-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diiso propylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-iso Propylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonyl Piperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4 -(4-(3-Hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4 -(2-N,N-Diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethyl ylaminotetrahydropyrrolyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,叔丁磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,二甲氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) Methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, tert-butanesulfonyl , methanesulfonylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethyl Aminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diethylaminocarbonyl Isopropylphosphinoyl.
在一些实施方案中,R1选自其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4--二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,4-(四氢吡咯-1-基)哌啶基;(3) piperidinyl, N-methyl-4-piperidinyl, 4--dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl Isopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4- Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonyl) acylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-Hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-( 4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl , 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-di Methylaminotetrahydropyrrolyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl;
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基或(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl or
(5)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(5) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents may be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自其中Z1,Z2,Z3,Z4,Z5各自独立地任选自:In some embodiments, R1 is selected from Wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)4-(四氢吡咯-1-基)哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-二甲氨基-哌啶基;(3) 4-(Tetrahydropyrrol-1-yl)piperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-dimethylamino-piperidinyl ;
(4)Z2与Z3可以形成含氮的取代或未取代的五元环 (4) Z 2 and Z 3 can form a nitrogen-containing substituted or unsubstituted five-membered ring
在一些实施方案中,R1选自:其中In some embodiments, R1 is selected from: in
Z1和Z5二者之一为氢,另一为甲氧基;One of Z 1 and Z 5 is hydrogen, and the other is methoxy;
Z3选自:4-二甲氨基-哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,或Z 3 is selected from: 4-dimethylamino-piperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidine pyridyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地任选自:In some embodiments, R2 is selected from: Wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢;(2)二异丙基次膦酰基,二乙基次膦酰基。(1) Hydrogen; (2) Diisopropylphosphinoyl, diethylphosphinoyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为二异丙基次膦酰基或二乙基次膦酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, the other is diisopropylphosphinoyl or diethylphosphinoyl; A 2 , A 3 and A 4 are all hydrogen.
第十七方面,本发明提供了一种下面通式IL表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,A seventeenth aspect, the present invention provides a compound represented by the following general formula IL, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,A为亚甲基;X为NH;Wherein, A is methylene; X is NH;
R1选自:R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(4)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(4) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidyl pyridyl,
(5)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,或(5) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl, or
(6)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(6) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲氧基,(2) Methoxy,
(3)4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,(3) 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl) piperidinyl,
(4)4-甲基哌嗪基,或(4) 4-methylpiperazinyl, or
(5)Z2与Z3或Z3与Z4形成 (5) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一为甲氧基;Z4为氢; Wherein one of Z 1 and Z 5 is hydrogen, the other is methoxy; Z 4 is hydrogen;
Z3选自:4-羟基哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,或Z 3 is selected from: 4-hydroxypiperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, or
Z2与Z3形成 Z 2 forms with Z 3
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)甲磺酰基。(1) Hydrogen, (2) Methanesulfonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为甲磺酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is methanesulfonyl; A 2 , A 3 and A 4 are all hydrogen.
第十八方面,本发明提供了一种下面通式IM表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In an eighteenth aspect, the present invention provides a compound represented by the following general formula IM, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,A为亚甲基;X为NH;Wherein, A is methylene; X is NH;
R1选自:R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自:其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基(2) C1-C6 alkoxy
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(4)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(4) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidyl pyridyl,
(5)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基或(5) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl or
(6)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(6) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地选自: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲氧基,(2) Methoxy,
(3)4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,(3) 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl) piperidinyl,
(4)4-甲基哌嗪基,或(4) 4-methylpiperazinyl, or
(5)Z2与Z3或Z3与Z4形成 (5) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一为甲氧基;Z4为氢; Wherein one of Z 1 and Z 5 is hydrogen, the other is methoxy; Z 4 is hydrogen;
Z3选自:4-羟基哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,或Z 3 is selected from: 4-hydroxypiperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, or
Z2与Z3形成 Z 2 forms with Z 3
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)异丙基磺酰基。(1) hydrogen, (2) isopropylsulfonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为异丙基磺酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, the other is isopropylsulfonyl; A 2 , A 3 and A 4 are all hydrogen.
第十九方面,本发明提供了一种下面通式IT表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a nineteenth aspect, the present invention provides a compound represented by the following general formula IT, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,A为亚甲基;X为O;Wherein, A is methylene; X is O;
R1选自:R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,4-(四氢吡咯-1-基)哌啶基(3) piperidinyl, N-methyl-4-piperidinyl, 4-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diiso propylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-iso Propylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonyl Piperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4 -(4-(3-Hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4 -(2-N,N-Diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethyl ylaminotetrahydropyrrolyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,叔丁磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,二甲氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) Methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, tert-butanesulfonyl , methanesulfonylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethyl Aminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diethylaminocarbonyl Isopropylphosphinoyl.
在一些实施方案中,R1选自其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4--二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,4-(四氢吡咯-1-基)哌啶基;(3) piperidinyl, N-methyl-4-piperidinyl, 4--dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl Isopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4- Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonyl) acylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-Hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-( 4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl , 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-di Methylaminotetrahydropyrrolyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl;
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基或(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl or
(5)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(5) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents may be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:其中Z1,Z2,Z3,Z4,Z5各自独立地任选自:In some embodiments, R1 is selected from: Wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,吗啉基,4-二甲氨基-哌啶基,(3) 4-methylpiperazinyl, 4-(4-methylpiperazinyl) piperidinyl, morpholinyl, 4-dimethylamino-piperidinyl,
(4)Z2与Z3可以形成含氮的取代或未取代的五元环 (4) Z 2 and Z 3 can form a nitrogen-containing substituted or unsubstituted five-membered ring
在一些实施方案中,R1选自:其中In some embodiments, R1 is selected from: in
Z1和Z5二者之一为氢,另一为甲氧基;One of Z 1 and Z 5 is hydrogen, and the other is methoxy;
Z3选自:4-二甲氨基-哌啶基,4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,4-甲基哌嗪基或吗啉基,或Z 3 is selected from: 4-dimethylamino-piperidinyl, 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-methylpiperazinyl or morpholinyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地任选自:In some embodiments, R2 is selected from: Wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢(1) Hydrogen
(2)异丙基磺酰基。(2) Isopropylsulfonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为异丙基磺酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, the other is isopropylsulfonyl; A 2 , A 3 and A 4 are all hydrogen.
第二十方面,本发明提供了一种下面通式IN表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a twentieth aspect, the present invention provides a compound represented by the following general formula IN, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) propylaminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-di Ethylaminopropyl, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6 cycloalkyl, 4 -N,N-Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-iso Propyl-4-piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-( N-methyl-4-piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, methanesulfonylamino , methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylamino Carbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethylphosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷基,(2) C1-C6 alkyl,
(3)C1-C6烷氧基,(3) C1-C6 alkoxy,
(4)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(4) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(5)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(5) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidinyl,
(6)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(6) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,或(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl, or
(8)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基。(8) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five- or six-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)甲基,甲氧基,(2) methyl, methoxy,
(3)4-羟基哌啶基,4-甲基哌嗪基,N-甲基-4-哌啶基,(3) 4-hydroxypiperidinyl, 4-methylpiperazinyl, N-methyl-4-piperidinyl,
(4)4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,氨基磺酰基,或(4) 4-(4-Methylpiperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl, aminosulfonyl, or
(5)Z2与Z3或Z3与Z4形成 (5) Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一为甲氧基; Wherein one of Z 1 and Z 5 is hydrogen, and the other is methoxy;
Z2和Z4二者之一为氢,另一为甲基,One of Z 2 and Z 4 is hydrogen, the other is methyl,
Z3选自:4-羟基哌啶基,4-甲基哌嗪基,N-甲基-4-哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,氨基磺酰基,或Z 3 is selected from: 4-hydroxypiperidinyl, 4-methylpiperazinyl, N-methyl-4-piperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(tetrakis Hydropyrrol-1-yl)piperidinyl, aminosulfonyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,甲亚磺酰基,乙亚磺酰基,甲磺酰基,乙磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基。(2) Methylthio, ethylthio, methanesulfinyl, ethylsulfinyl, methanesulfonyl, ethanesulfonyl, methanesulfonylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, iso Propoxycarbonyl, n-butoxycarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl.
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地选自:In some embodiments, R2 is selected from: wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,(2)甲氧羰基。(1) Hydrogen, (2) Methoxycarbonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为甲氧羰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is methoxycarbonyl; A 2 , A 3 and A 4 are all hydrogen.
第二十一方面,本发明提供了一种下面通式IU表示的化合物、其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,In a twenty-first aspect, the present invention provides a compound represented by the following general formula IU, its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate,
其中,R1选自:where R1 is selected from:
1)C1-C6烷基,2-N,N-二甲基氨基乙基,2-羟基乙基,2-N,N-二乙基氨基乙基,2-N,N-二异丙基氨基乙基,2-吗啉基乙基,2-(4-甲基哌嗪基)乙基,3-N,N-二甲基氨基丙基,3-N,N-二乙基氨基丙基,3-N,N-二异丙基氨基丙基,3-吗啉基丙基,3-(4-甲基哌嗪)基丙基,C3-C6环烷基,4-N,N-二甲基氨基环己基,4-N,N-二乙基氨基环己基,N-甲基-4-哌啶基,N-乙基-4-哌啶基,N-异丙基-4-哌啶基,1,3-二甲基-5-吡唑基,1-甲基-4-吡唑基,3-甲基-5-异噁唑啉基,1-(N-甲基-4-哌啶基)-4-吡唑基,1-(N-叔丁氧羰基-4-哌啶基)-4-吡唑基;1) C1-C6 alkyl, 2-N,N-dimethylaminoethyl, 2-hydroxyethyl, 2-N,N-diethylaminoethyl, 2-N,N-diisopropyl Aminoethyl, 2-morpholinoethyl, 2-(4-methylpiperazinyl)ethyl, 3-N,N-dimethylaminopropyl, 3-N,N-diethylaminopropyl Base, 3-N,N-diisopropylaminopropyl, 3-morpholinylpropyl, 3-(4-methylpiperazinyl)propyl, C3-C6cycloalkyl, 4-N,N -Dimethylaminocyclohexyl, 4-N,N-diethylaminocyclohexyl, N-methyl-4-piperidinyl, N-ethyl-4-piperidinyl, N-isopropyl-4 -Piperidinyl, 1,3-dimethyl-5-pyrazolyl, 1-methyl-4-pyrazolyl, 3-methyl-5-isoxazolinyl, 1-(N-methyl -4-Piperidinyl)-4-pyrazolyl, 1-(N-tert-butoxycarbonyl-4-piperidinyl)-4-pyrazolyl;
2)其中Z1,Z2,Z3,Z4,Z5各自独立地选自:2) wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,硝基,氰基,(1) hydrogen, fluorine, chlorine, bromine, iodine, nitro, cyano,
(2)C1-C6烷基,C1-C6烷氧基,C1-C6含氧烷基,C1-C6含氟烷基,C1-C6含氟烷氧基,(2) C1-C6 alkyl, C1-C6 alkoxy, C1-C6 oxygen-containing alkyl, C1-C6 fluorine-containing alkyl, C1-C6 fluorine-containing alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基,4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl, 4-(4-methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4- (4-Isopropylpiperazinyl)piperidinyl, 4-(4-acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4 -Methylsulfonylpiperazinyl)piperidyl, 4-(4-(2-hydroxyethyl)piperazinyl)piperidyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidyl pyridyl, 4-(4-(3-hydroxypropyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-Diethylaminoethyl)piperazinyl)piperidyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl) piperidinyl, 4-(4-(3-N,N-diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrolyl)piperidinyl, 4-(3-N, N-dimethylaminotetrahydropyrrolyl) piperidinyl,
(4)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,(4) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl,
(5)N,N-二甲基氨基,N,N-二乙基氨基,N,N-二异丙基氨基,2-N,N-二甲基氨基乙基氨基,2-吗啉基乙基氨基,2-(4-甲基哌嗪基)乙基氨基,3-N,N-二甲基氨基丙基氨基,3-N,N-二乙基氨基丙基氨基,3-N,N-二异丙基氨基丙基氨基,3-吗啉基丙基氨基,3-(4-甲基哌嗪基)丙基氨基,N-甲基哌啶-4-氨基,N-乙基哌啶-4-氨基,N-异丙基哌啶-4-氨基,(5) N,N-dimethylamino, N,N-diethylamino, N,N-diisopropylamino, 2-N,N-dimethylaminoethylamino, 2-morpholino Ethylamino, 2-(4-methylpiperazinyl)ethylamino, 3-N,N-dimethylaminopropylamino, 3-N,N-diethylaminopropylamino, 3-N ,N-diisopropylaminopropylamino, 3-morpholinopropylamino, 3-(4-methylpiperazinyl)propylamino, N-methylpiperidine-4-amino, N-ethyl piperidine-4-amino, N-isopropylpiperidine-4-amino,
(6)2-N,N-二甲基氨基乙氧基,2-N,N-二乙基氨基乙氧基,2-N,N-二异丙基氨基乙氧基,2-(4-甲基哌嗪基)乙氧基,2-(4-乙酰基哌嗪基)乙氧基,2-吗啉基乙氧基,2-硫啡啉基乙氧基,2-哌啶基乙氧基,3-N,N-二甲基氨基丙氧基,3-N,N-二乙基氨基丙氧基,3-N,N-二异丙基氨基丙氧基,3-(4-甲基哌嗪基)丙氧基,3-(4-乙酰基哌嗪基)丙氧基,3-吗啉基丙氧基,3-硫啡啉基丙氧基,3-哌啶基丙氧基,吡啶-2-基甲氧基,吡啶-3-基甲氧基,吡啶-4-基甲氧基,苯基甲氧基,单卤素取代苯基甲氧基,偕二卤素取代苯基甲氧基,杂二卤素取代苯基甲氧基,(6) 2-N,N-dimethylaminoethoxy, 2-N,N-diethylaminoethoxy, 2-N,N-diisopropylaminoethoxy, 2-(4 -Methylpiperazinyl)ethoxy, 2-(4-acetylpiperazinyl)ethoxy, 2-morpholinylethoxy, 2-thiophenarinylethoxy, 2-piperidinyl Ethoxy, 3-N,N-dimethylaminopropoxy, 3-N,N-diethylaminopropoxy, 3-N,N-diisopropylaminopropoxy, 3-( 4-Methylpiperazinyl)propoxy, 3-(4-Acetylpiperazinyl)propoxy, 3-morpholinopropoxy, 3-thiophenarinylpropoxy, 3-piperidine pyridin-2-ylmethoxy, pyridin-3-ylmethoxy, pyridin-4-ylmethoxy, phenylmethoxy, monohalogen substituted phenylmethoxy, geminal dihalogen Substituted phenylmethoxy, heterodihalogen substituted phenylmethoxy,
(7)羟基磺酰基,氨基磺酰基,甲氨基磺酰基,乙氨基磺酰基,丙氨基磺酰基,异丙氨基磺酰基,环丙基氨基磺酰基,环丁基氨基磺酰基,环戊基氨基磺酰基,哌啶-1-基磺酰基,4-羟基哌啶-1-基磺酰基,4-N,N-二甲基氨基哌啶-1-基磺酰基,4-N,N-二乙基氨基哌啶-1-基磺酰基,四氢吡咯基-1-磺酰基,3-N,N-二甲基氨基四氢吡咯基-1-磺酰基,3-N,N-二乙基氨基四氢吡咯基-1-磺酰基,4-甲基哌嗪-1-基磺酰基,4-乙基哌嗪基-1-磺酰基,4-乙酰基哌嗪基-1-磺酰基,4-叔丁氧羰基哌嗪基-1-磺酰基,4-(2-羟基乙基)哌嗪基-1-磺酰基,4-(2-氰基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-磺酰基,4-(2-N,N-二乙基乙基)哌嗪基-1-磺酰基,4-(3-羟基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-磺酰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-磺酰基,吗啉基-1-磺酰基,3,5-二甲基吗啉基-1-磺酰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基磺酰基,4-(4-乙基-1-哌嗪基)哌啶-1-基磺酰基,4-(4-乙酰基-1-哌嗪基)哌啶-1-基磺酰基,4-(N-甲基-4-哌啶基)哌嗪基-1-磺酰基,(7) Hydroxysulfonyl, aminosulfonyl, methylaminosulfonyl, ethylaminosulfonyl, propylaminosulfonyl, isopropylaminosulfonyl, cyclopropylaminosulfonyl, cyclobutylaminosulfonyl, cyclopentylamino Sulfonyl, piperidin-1-ylsulfonyl, 4-hydroxypiperidin-1-ylsulfonyl, 4-N,N-dimethylaminopiperidin-1-ylsulfonyl, 4-N,N-di Ethylaminopiperidin-1-ylsulfonyl, tetrahydropyrrolyl-1-sulfonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-sulfonyl, 3-N,N-diethyl ylaminotetrahydropyrrolyl-1-sulfonyl, 4-methylpiperazin-1-ylsulfonyl, 4-ethylpiperazinyl-1-sulfonyl, 4-acetylpiperazinyl-1-sulfonyl , 4-tert-butoxycarbonylpiperazinyl-1-sulfonyl, 4-(2-hydroxyethyl)piperazinyl-1-sulfonyl, 4-(2-cyanoethyl)piperazinyl-1- Sulfonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-sulfonyl, 4-(2-N,N-diethylethyl)piperazinyl-1-sulfonyl Acyl, 4-(3-hydroxypropyl)piperazinyl-1-sulfonyl, 4-(3-N,N-dimethylaminopropyl)piperazinyl-1-sulfonyl, 4-(3- N,N-Diethylaminopropyl)piperazinyl-1-sulfonyl, morpholinyl-1-sulfonyl, 3,5-dimethylmorpholinyl-1-sulfonyl, 4-(4- Methyl-piperazin-1-yl)piperidin-1-ylsulfonyl, 4-(4-ethyl-1-piperazinyl)piperidin-1-ylsulfonyl, 4-(4-acetyl- 1-Piperazinyl)piperidin-1-ylsulfonyl, 4-(N-methyl-4-piperidinyl)piperazinyl-1-sulfonyl,
(8)羟基羰基,氨基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,哌啶基-1-羰基,4-羟基哌啶基-1-羰基,4-N,N-二甲基氨基哌啶基-1-羰基,4-N,N-二乙基氨基哌啶基-1-羰基,四氢吡咯基-1-羰基,3-N,N-二甲基氨基四氢吡咯基-1-羰基,3-N,N-二乙基氨基四氢吡咯基-1-羰基,4-甲基哌嗪-1-基羰基,4-乙基哌嗪基-1-羰基,4-乙酰基哌嗪基-1-羰基,4-叔丁氧羰基哌嗪基-1-羰基,4-(2-羟基乙基)哌嗪基-1-羰基,4-(2-氰基乙基)哌嗪基-1-羰基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-羰基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-羰基,4-(3-羟基丙基)哌嗪基-1-羰基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-羰基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-羰基,吗啉基-1-羰基,3,5-二甲基吗啉基-1-羰基,4-(4-甲基-哌嗪-1-基)哌啶-1-基羰基,4-(4-乙基-1-哌嗪基)哌啶基-1-羰基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-羰基,4-(N-甲基-4-哌啶基)哌嗪基-1-羰基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,(8) Hydroxycarbonyl, aminocarbonyl, methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, piperidinyl-1- Carbonyl, 4-hydroxypiperidinyl-1-carbonyl, 4-N,N-dimethylaminopiperidinyl-1-carbonyl, 4-N,N-diethylaminopiperidinyl-1-carbonyl, tetra Hydropyrrolyl-1-carbonyl, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carbonyl, 3-N,N-diethylaminotetrahydropyrrolyl-1-carbonyl, 4-methyl Piperazin-1-ylcarbonyl, 4-ethylpiperazinyl-1-carbonyl, 4-acetylpiperazinyl-1-carbonyl, 4-tert-butoxycarbonylpiperazinyl-1-carbonyl, 4-(2 -Hydroxyethyl)piperazinyl-1-carbonyl, 4-(2-cyanoethyl)piperazinyl-1-carbonyl, 4-(2-N,N-dimethylaminoethyl)piperazinyl -1-carbonyl, 4-(2-N,N-diethylaminoethyl)piperazinyl-1-carbonyl, 4-(3-hydroxypropyl)piperazinyl-1-carbonyl, 4-(3 -N,N-Dimethylaminopropyl)piperazinyl-1-carbonyl, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carbonyl, morpholinyl-1- Carbonyl, 3,5-dimethylmorpholinyl-1-carbonyl, 4-(4-methyl-piperazin-1-yl)piperidin-1-ylcarbonyl, 4-(4-ethyl-1- Piperazinyl)piperidinyl-1-carbonyl, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carbonyl, 4-(N-methyl-4-piperidinyl)piperazine yl-1-carbonyl, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl,
(9)氨基甲酰氨基,甲氨基甲酰氨基,乙氨基甲酰氨基,丙氨基甲酰氨基,异丙氨基甲酰氨基,环丙基氨基甲酰氨基,环丁基氨基甲酰氨基,环戊基氨基甲酰氨基,哌啶基-1-甲酰氨基,4-羟基哌啶基-1-甲酰氨基,4-N,N-二甲基氨基哌啶基-1-甲酰氨基,4-N,N-二乙基氨基哌啶基-1-甲酰氨基,四氢吡咯基-1-甲酰氨基,3-N,N-二甲基氨基四氢吡咯基-1-甲酰氨基,3-N,N-二乙基氨基四氢吡咯基-1-甲酰氨基,4-甲基哌嗪基-1-甲酰氨基,4-乙基哌嗪基-1-甲酰氨基,4-乙酰基哌嗪基-1-甲酰氨基,4-叔丁氧羰基哌嗪基-1-甲酰氨基,4-(2-羟基乙基)哌嗪基-1-甲酰氨基,4-(2-氰基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二甲基氨基乙基)哌嗪基-1-甲酰氨基,4-(2-N,N-二乙基氨基乙基)哌嗪基-1-甲酰氨基,4-(3-羟基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二甲基氨基丙基)哌嗪基-1-甲酰氨基,4-(3-N,N-二乙基氨基丙基)哌嗪基-1-甲酰氨基,吗啉基-1-甲酰氨基,3,5-二甲基吗啉基-1-甲酰氨基,4-(4-甲基-哌嗪-1-基)哌啶基-1-甲酰氨基,4-(4-乙基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(4-乙酰基-1-哌嗪基)哌啶基-1-甲酰氨基,4-(N-甲基-4-哌啶基)哌嗪基-1-甲酰氨基;或(9) carbamoylamino, methylcarbamoylamino, ethylcarbamoylamino, propylcarbamoylamino, isopropylcarbamoylamino, cyclopropylcarbamoylamino, cyclobutylcarbamoylamino, cyclo Amylcarbamoylamino, piperidinyl-1-carboxamido, 4-hydroxypiperidinyl-1-carboxamido, 4-N,N-dimethylaminopiperidinyl-1-carboxamido, 4-N,N-Diethylaminopiperidinyl-1-carboxamido, tetrahydropyrrolyl-1-carboxamido, 3-N,N-dimethylaminotetrahydropyrrolyl-1-carboxyl Amino, 3-N,N-diethylaminotetrahydropyrrolyl-1-carboxamido, 4-methylpiperazinyl-1-carboxamido, 4-ethylpiperazinyl-1-carboxamido , 4-Acetyl piperazinyl-1-carboxamido, 4-tert-butoxycarbonyl piperazinyl-1-carboxamido, 4-(2-hydroxyethyl) piperazinyl-1-carboxamido, 4-(2-cyanoethyl)piperazinyl-1-carboxamido, 4-(2-N,N-dimethylaminoethyl)piperazinyl-1-carboxamido, 4-(2 -N,N-Diethylaminoethyl)piperazinyl-1-carboxamido, 4-(3-hydroxypropyl)piperazinyl-1-carboxamido, 4-(3-N,N- Dimethylaminopropyl)piperazinyl-1-carboxamido, 4-(3-N,N-diethylaminopropyl)piperazinyl-1-carboxamido, morpholino-1-methyl amido, 3,5-dimethylmorpholino-1-carboxamido, 4-(4-methyl-piperazin-1-yl)piperidinyl-1-carboxamido, 4-(4- Ethyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(4-acetyl-1-piperazinyl)piperidinyl-1-carboxamido, 4-(N-methyl -4-Piperidinyl)piperazinyl-1-carboxamido; or
(10)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环或六元环,取代基可以选自与Z1相同的上述取代基;(10) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring or six-membered ring, and the substituents can be selected from the same substituents as Z 1 ;
R2选自其中A1,A2,A3,A4,A5各自独立地选自:R2 is selected from wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢,氟,氯,溴,碘,氰基,三氟甲基,三氟甲氧基,硝基,(1) hydrogen, fluorine, chlorine, bromine, iodine, cyano, trifluoromethyl, trifluoromethoxy, nitro,
(2)甲硫基,乙硫基,异丙硫基,甲亚磺酰基,乙亚磺酰基,异丙亚磺酰基,甲磺酰基,乙磺酰基,异丙基磺酰基,叔丁磺酰基,二甲氨基磺酰基,甲磺酰氨基,甲氧基羰基,乙氧基羰基,丙氧基羰基,异丙氧基羰基,正丁氧基羰基,异丁氧基羰基,叔丁氧基羰基,甲氨基羰基,乙氨基羰基,丙氨基羰基,异丙氨基羰基,二甲氨基羰基,环丙基氨基羰基,环丁基氨基羰基,环戊基氨基羰基,二甲基次膦酰基,二乙基次膦酰基,二异丙基次膦酰基。(2) Methylthio, ethylthio, isopropylthio, methylsulfinyl, ethylsulfinyl, isopropylsulfinyl, methylsulfonyl, ethylsulfonyl, isopropylsulfonyl, tert-butanesulfonyl , dimethylaminosulfonyl, mesylamino, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, n-butoxycarbonyl, isobutoxycarbonyl, tert-butoxycarbonyl , methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl, isopropylaminocarbonyl, dimethylaminocarbonyl, cyclopropylaminocarbonyl, cyclobutylaminocarbonyl, cyclopentylaminocarbonyl, dimethylphosphinoyl, diethyl phosphinoyl, diisopropylphosphinoyl.
在一些实施方案中,R1选自:其中Z1,Z2,Z3,Z4,Z5各自独立地选自:In some embodiments, R1 is selected from: wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)哌啶基,N-甲基-4-哌啶基,4-N,N-二甲基氨基哌啶基,4-N,N-二乙基氨基哌啶基,4-N,N-二异丙基氨基哌啶基,4-羟基哌啶基(3) piperidinyl, N-methyl-4-piperidinyl, 4-N,N-dimethylaminopiperidinyl, 4-N,N-diethylaminopiperidinyl, 4-N, N-diisopropylaminopiperidinyl, 4-hydroxypiperidinyl
(4)4-(4-甲基哌嗪基)哌啶基,4-(4-乙基哌嗪基)哌啶基,4-(4-异丙基哌嗪基)哌啶基,4-(4-乙酰基哌嗪基)哌啶基,4-(4-叔丁氧羰基哌嗪基)哌啶基,4-(4-甲磺酰基哌嗪基)哌啶基,4-(4-(2-羟基乙基)哌嗪基)哌啶基,4-(4-(2-氰基乙基)哌嗪基)哌啶基,4-(4-(3-羟基丙基)哌嗪基)哌啶基,4-(4-(2-N,N-二甲基氨基乙基)哌嗪基)哌啶基,4-(4-(2-N,N-二乙基氨基乙基)哌嗪基)哌啶基,4-(4-(3-N,N-二甲基氨基丙基)哌嗪基)哌啶基,4-(4-(3-N,N-二乙基氨基丙基)哌嗪基)哌啶基,4-(四氢吡咯-1-基)哌啶基,4-(3-N,N-二甲基氨基四氢吡咯基)哌啶基,(4) 4-(4-Methylpiperazinyl)piperidinyl, 4-(4-ethylpiperazinyl)piperidinyl, 4-(4-isopropylpiperazinyl)piperidinyl, 4 -(4-Acetylpiperazinyl)piperidinyl, 4-(4-tert-butoxycarbonylpiperazinyl)piperidinyl, 4-(4-methanesulfonylpiperazinyl)piperidinyl, 4-( 4-(2-Hydroxyethyl)piperazinyl)piperidinyl, 4-(4-(2-cyanoethyl)piperazinyl)piperidinyl, 4-(4-(3-hydroxypropyl) Piperazinyl) piperidinyl, 4-(4-(2-N,N-dimethylaminoethyl)piperazinyl)piperidinyl, 4-(4-(2-N,N-diethyl) Aminoethyl)piperazinyl)piperidinyl, 4-(4-(3-N,N-dimethylaminopropyl)piperazinyl)piperidinyl, 4-(4-(3-N,N -Diethylaminopropyl)piperazinyl)piperidinyl, 4-(tetrahydropyrrol-1-yl)piperidinyl, 4-(3-N,N-dimethylaminotetrahydropyrrolyl)piperidyl pyridyl,
(5)4-甲基哌嗪基,4-乙基哌嗪基,4-异丙基哌嗪基,4-乙酰基哌嗪基,4-叔丁氧羰基哌嗪基,4-甲磺酰基哌嗪基,4-(2-羟基乙基)哌嗪基,4-(2-氰基乙基)哌嗪基,4-(3-羟基丙基)哌嗪基,4-(2-N,N-二甲基氨基乙基)哌嗪基,4-(2-N,N-二乙基氨基乙基)哌嗪基,4-(3-N,N-二甲基氨基丙基)哌嗪基,4-(3-N,N-二乙基氨基丙基)哌嗪基,4-(N-甲基-4-哌啶基)哌嗪基,4-(N-乙基-4-哌啶基)哌嗪基,或(5) 4-methylpiperazinyl, 4-ethylpiperazinyl, 4-isopropylpiperazinyl, 4-acetylpiperazinyl, 4-tert-butoxycarbonylpiperazinyl, 4-methanesulfonic acid Acylpiperazinyl, 4-(2-hydroxyethyl)piperazinyl, 4-(2-cyanoethyl)piperazinyl, 4-(3-hydroxypropyl)piperazinyl, 4-(2- N,N-Dimethylaminoethyl)piperazinyl, 4-(2-N,N-diethylaminoethyl)piperazinyl, 4-(3-N,N-dimethylaminopropyl ) piperazinyl, 4-(3-N,N-diethylaminopropyl)piperazinyl, 4-(N-methyl-4-piperidinyl)piperazinyl, 4-(N-ethyl -4-Piperidinyl)piperazinyl, or
(6)Z2与Z3或Z3与Z4形成含氮或含氧的取代或未取代的五元环,取代基可以选自与Z1相同的上述取代基。(6) Z 2 and Z 3 or Z 3 and Z 4 form a nitrogen- or oxygen-containing substituted or unsubstituted five-membered ring, and the substituents can be selected from the same substituents as those of Z 1 .
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1,Z2,Z3,Z4,Z5各自独立地任选自: Wherein Z 1 , Z 2 , Z 3 , Z 4 , Z 5 are each independently selected from:
(1)氢,(1) Hydrogen,
(2)C1-C6烷氧基,(2) C1-C6 alkoxy,
(3)4-(4-甲基哌嗪基)哌啶基,4-甲基哌嗪基,(3) 4-(4-methylpiperazinyl) piperidinyl, 4-methylpiperazinyl,
(4)Z2与Z3可以形成含氮的取代或未取代的五元环 (4) Z 2 and Z 3 can form a nitrogen-containing substituted or unsubstituted five-membered ring
在一些实施方案中,R1选自:In some embodiments, R1 is selected from:
其中Z1和Z5二者之一为氢,另一为甲氧基; Wherein one of Z 1 and Z 5 is hydrogen, and the other is methoxy;
Z3选自:4-甲基哌嗪基,4-(4-甲基哌嗪基)哌啶基,或Z 3 is selected from: 4-methylpiperazinyl, 4-(4-methylpiperazinyl)piperidyl, or
Z2与Z3或Z3与Z4形成 Z 2 and Z 3 or Z 3 and Z 4 form
在一些实施方案中,R2选自:其中A1,A2,A3,A4,A5各自独立地任选自:In some embodiments, R2 is selected from: Wherein A 1 , A 2 , A 3 , A 4 , A 5 are each independently selected from:
(1)氢(1) Hydrogen
(2)二甲氨基磺酰基。(2) Dimethylaminosulfonyl.
在一些实施方案中,R2选自:其中A1和A5二者之一为氢,另一为二甲氨基磺酰基;A2,A3,A4都为氢。In some embodiments, R2 is selected from: One of A 1 and A 5 is hydrogen, and the other is dimethylaminosulfonyl; A 2 , A 3 and A 4 are all hydrogen.
除非特殊说明,上述基团和取代基具有药物化学领域的普通含义。Unless otherwise specified, the above-mentioned groups and substituents have their ordinary meanings in the field of medicinal chemistry.
需要说明的是,C1-C6含氧烷基是指是指C1-C6烷基骨架被一个或多个C1-C6烷氧基取代所成的基团,例如,甲氧基乙基,甲氧基乙氧基甲基等。It should be noted that the C1-C6 oxyalkyl group refers to the group formed by the substitution of the C1-C6 alkyl skeleton with one or more C1-C6 alkoxy groups, for example, methoxyethyl, methoxy ethoxymethyl, etc.
术语“C1-C6烷基”指的是任意的含有1-6个碳原子的直链或支链基团,例如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基、仲丁基、正戊基、叔戊基、正己基等。The term "C 1 -C 6 alkyl" refers to any straight or branched chain group containing 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, Isobutyl, tert-butyl, sec-butyl, n-pentyl, tert-amyl, n-hexyl, etc.
术语“C2-C6烯基”指的是任意的含有2-6个碳原子且含有至少一个烯基的直链或支链基团基团,例如乙烯基、烯丙基、1-丙烯基、异丙烯基、1-丁烯基、2-丁烯基、3-丁烯基、2-戊烯基、1-己烯基等。The term "C 2 -C 6 alkenyl" refers to any straight or branched chain radical group containing 2 to 6 carbon atoms and containing at least one alkenyl group, such as vinyl, allyl, 1-propene group, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 1-hexenyl and the like.
术语“C2-C6炔基”指的是任意的含有2-6个碳原子且含有至少一个炔基的直链或支链基团,例如乙炔基、2-丙炔基、4-戊炔基等。The term "C 2 -C 6 alkynyl" refers to any straight or branched chain group containing 2 to 6 carbon atoms and containing at least one alkynyl group, such as ethynyl, 2-propynyl, 4-pentynyl Alkynyl etc.
根据本发明和除非另有提供,任意上述基团可以任选地在其任意自由位置上被一个或多个基团取代,例如被1-6个基团取代,该基团独立地选自:卤素原子、硝基、氧代(=O)、氰基、C1-C6烷基、多氟化烷基、多氟化烷氧基、烯基、炔基、羟基烷基、羟基烷基氨基、羟基杂环基、芳基、芳基-烷基、杂芳基、杂芳基-烷基、杂环基、杂环基-烷基、C3-C7环烷基、环烷基-烷基、烷基-芳基、烷基-杂芳基、烷基-杂环基、烷基-环烷基、烷基-芳基-烷基、烷基-杂芳基-烷基、烷基-杂环基-烷基、烷基-环烷基-烷基、烷基-杂环基-杂环基、杂环基-杂环基、杂环基-烷基-杂环基、杂环基-烷基氨基、烷基-杂环基-烷基-氨基、羟基、烷氧基、芳氧基、杂环基氧基、烷基-杂环基氧基、亚甲二氧基、烷基羰基氧基、芳基羰基氧基、环烯基氧基、杂环基羰基氧基、亚烷基氨基氧基、羧基、烷氧基羰基、芳氧基羰基、环烷基氧基羰基、杂环基氧基羰基、氨基、脲基、烷基氨基、氨基-烷基氨基、二烷基氨基、二烷基氨基-杂环基、二烷基氨基-烷基氨基、芳基氨基、芳基烷基氨基、二芳基氨基、杂环基氨基、烷基-杂环基氨基、烷基-杂环基羰基、羰基氨基、烷基羰基氨基、芳基羰基氨基、杂环基羰基氨基、烷基-杂环基羰基氨基、氨基羰基、烷基氨基羰基、二烷基氨基羰基、芳基氨基羰基、杂环基氨基羰基、烷氧基羰基氨基、烷氧基羰基氨基-烷基氨基、烷氧基羰基杂环基-烷基氨基、烷氧基-芳基-烷基、羟基氨基-羰基、烷氧基亚氨基、烷基磺酰基氨基、芳基磺酰基氨基、杂环基磺酰基氨基、甲酰基、烷基羰基、芳基羰基、环烷基羰基、杂环基羰基、烷基磺酰基、芳基磺酰基、氨基磺酰基、烷基氨基磺酰基、二烷基氨基磺酰基、芳基氨基磺酰基、杂环基氨基磺酰基、芳硫基、烷硫基、膦酸酯基和烷基膦酸酯基。According to the present invention and unless otherwise provided, any of the above groups may be optionally substituted at any of its free positions with one or more groups, such as 1-6 groups, independently selected from: Halogen atom, nitro group, oxo (=O), cyano group, C 1 -C 6 alkyl group, polyfluorinated alkyl group, polyfluorinated alkoxy group, alkenyl group, alkynyl group, hydroxyalkyl group, hydroxyalkyl group amino, hydroxyheterocyclyl, aryl, aryl-alkyl, heteroaryl, heteroaryl-alkyl, heterocyclyl, heterocyclyl-alkyl, C3 - C7cycloalkyl , cycloalkyl -Alkyl, alkyl-aryl, alkyl-heteroaryl, alkyl-heterocyclyl, alkyl-cycloalkyl, alkyl-aryl-alkyl, alkyl-heteroaryl-alkyl, Alkyl-heterocyclyl-alkyl, alkyl-cycloalkyl-alkyl, alkyl-heterocyclyl-heterocyclyl, heterocyclyl-heterocyclyl, heterocyclyl-alkyl-heterocyclyl, Heterocyclyl-alkylamino, alkyl-heterocyclyl-alkyl-amino, hydroxy, alkoxy, aryloxy, heterocyclyloxy, alkyl-heterocyclyloxy, methylenedioxy , alkylcarbonyloxy, arylcarbonyloxy, cycloalkenyloxy, heterocyclylcarbonyloxy, alkyleneaminooxy, carboxyl, alkoxycarbonyl, aryloxycarbonyl, cycloalkyloxy carbonyl, heterocyclyloxycarbonyl, amino, ureido, alkylamino, amino-alkylamino, dialkylamino, dialkylamino-heterocyclyl, dialkylamino-alkylamino, arylamino , arylalkylamino, diarylamino, heterocyclylamino, alkyl-heterocyclylamino, alkyl-heterocyclylcarbonyl, carbonylamino, alkylcarbonylamino, arylcarbonylamino, heterocyclylcarbonyl Amino, alkyl-heterocyclylcarbonylamino, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, arylaminocarbonyl, heterocyclylaminocarbonyl, alkoxycarbonylamino, alkoxycarbonylamino-alkyl Amino, alkoxycarbonylheterocyclyl-alkylamino, alkoxy-aryl-alkyl, hydroxyamino-carbonyl, alkoxyimino, alkylsulfonylamino, arylsulfonylamino, heterocyclyl Sulfonylamino, formyl, alkylcarbonyl, arylcarbonyl, cycloalkylcarbonyl, heterocyclylcarbonyl, alkylsulfonyl, arylsulfonyl, aminosulfonyl, alkylaminosulfonyl, dialkylaminosulfonyl Acyl, arylaminosulfonyl, heterocyclylaminosulfonyl, arylthio, alkylthio, phosphonate and alkylphosphonate.
进而,如果适合,上述取代基各自可以进一步被一个或多个上述举出的基团取代。Furthermore, each of the aforementioned substituents may be further substituted with one or more of the aforementioned groups, if appropriate.
在这方面,术语“卤原子”指的是氟、氯、溴或碘原子。In this regard, the term "halogen atom" refers to a fluorine, chlorine, bromine or iodine atom.
术语“氰基”指的是-CN残基。The term "cyano" refers to a -CN residue.
术语“硝基”指的是-NO2基团。The term "nitro" refers to the -NO 2 group.
术语“烷氧基”、“环基氧基”、“芳基氧基”,“杂环基氧基”及其衍生物指的是任意上述C1-C6烷基、C3-C7环烷基、芳基或杂环基,其通过氧原子(-O-)连接到分子的其余部分。The terms "alkoxy", "cyclyloxy", "aryloxy", "heterocyclyloxy" and derivatives thereof refer to any of the aforementioned C1 - C6 alkyl, C3 - C7 Cycloalkyl, aryl, or heterocyclyl, which is attached to the rest of the molecule through an oxygen atom (-O-).
术语"芳基"是指单-、二-或多-碳环烃,其具有任选地进一步通过单键彼此稠合或连接的1至2个环系统,其中所述碳环中至少一个是“芳族的”,其中术语“芳族的”是指完全共轭的π-电子键系统。芳基环可以任选地进一步稠合或连接于芳族的和非芳族的碳环和杂环的环。所述芳基的非限制性的实例是苯基、α-或β-萘基。The term "aryl" refers to a mono-, di- or poly-carbocyclic hydrocarbon having 1 to 2 ring systems optionally further fused or linked to each other by single bonds, wherein at least one of the carbocyclic rings is "Aromatic" wherein the term "aromatic" refers to a fully conjugated pi-electron bond system. The aryl ring can optionally be further fused or attached to aromatic and non-aromatic carbocyclic and heterocyclic rings. Non-limiting examples of such aryl groups are phenyl, alpha- or beta-naphthyl.
术语"杂芳基"是指芳族的杂环,通常为具有1至3个选自N、O或S的杂原子的5-至8-元的杂环;杂芳基环可以任选地进一步稠合或连接于芳族和非芳族的碳环和杂环。所述杂芳基的非限制性的实例为例如吡啶基、吡嗪基、嘧啶基、哒嗪基、吲哚基、咪唑基、噻唑基、异噻唑基、噻噁唑基、吡咯基、苯基-吡咯基、呋喃基、苯基-呋喃基、噁唑基、异噁唑基、吡唑基、噻吩基、苯并噻吩基、异二氢吲哚基、苯并咪唑基、吲唑基、喹啉基、异喹啉基、1,2,3-三唑基、1-苯基-1,2,3-三唑基、2,3-二氢吲哚基、2,3-二氢苯并呋喃基、2,3-二氢苯并噻吩基、苯并吡喃基、2,3-二氢苯并噁嗪基、2,3-二氢喹喔啉基等。The term "heteroaryl" refers to an aromatic heterocycle, typically a 5- to 8-membered heterocycle having 1 to 3 heteroatoms selected from N, O or S; the heteroaryl ring may optionally Further fused or attached to aromatic and non-aromatic carbocyclic and heterocyclic rings. Non-limiting examples of such heteroaryl groups are eg pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, isothiazolyl, thioxazolyl, pyrrolyl, benzene yl-pyrrolyl, furyl, phenyl-furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzothienyl, isoindoline, benzimidazolyl, indazolyl , quinolinyl, isoquinolinyl, 1,2,3-triazolyl, 1-phenyl-1,2,3-triazolyl, 2,3-indoline, 2,3-diazolyl Hydrobenzofuranyl, 2,3-dihydrobenzothienyl, benzopyranyl, 2,3-dihydrobenzoxazinyl, 2,3-dihydroquinoxalinyl and the like.
术语“杂环基”(也称作“杂环烷基”)指的是3-、4-、5-、6-和7-元饱和或部分不饱和碳环,其中一个或多个碳原子被杂原子例如氮、氧和硫替代。杂环基的非限制性实例是,例如吡喃、吡咯烷、吡咯啉、咪唑啉、咪唑烷、吡唑烷、吡唑啉、噻唑啉、噻唑烷、二氢呋喃、四氢呋喃、1,3-二氧戊环、哌啶、哌嗪、吗啉、四氢吡咯基、硫吗啉基等。The term "heterocyclyl" (also referred to as "heterocycloalkyl") refers to 3-, 4-, 5-, 6-, and 7-membered saturated or partially unsaturated carbocyclic rings in which one or more carbon atoms Replaced by heteroatoms such as nitrogen, oxygen and sulfur. Non-limiting examples of heterocyclyl groups are, for example, pyran, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3- Dioxolane, piperidine, piperazine, morpholine, tetrahydropyrrolyl, thiomorpholinyl and the like.
术语“含氮或含氧的取代或未取代的五元环或六元环”,指的是5-或6-元饱和或部分不饱和碳环,其中一个或多个碳原子被杂原子例如氮、氧替代。含氮或含氧的取代或未取代的五元环或六元环选自吡咯烷、吡咯啉、吡咯、咪唑啉、咪唑烷、咪唑、吡唑烷、吡唑啉、吡唑、二氢呋喃、四氢呋喃、呋喃、1,3-二氧戊环、噁唑、二氢噁唑;吡啶、吡嗪、嘧啶、哒嗪、吡喃、哌啶、哌嗪、吗啉等。The term "nitrogen- or oxygen-containing substituted or unsubstituted five- or six-membered ring" refers to a 5- or 6-membered saturated or partially unsaturated carbocyclic ring in which one or more carbon atoms are replaced by heteroatoms such as Nitrogen and oxygen replacement. A nitrogen- or oxygen-containing substituted or unsubstituted five- or six-membered ring is selected from pyrrolidine, pyrroline, pyrrole, imidazoline, imidazolidine, imidazole, pyrazolidine, pyrazoline, pyrazole, dihydrofuran , tetrahydrofuran, furan, 1,3-dioxolane, oxazole, dihydrooxazole; pyridine, pyrazine, pyrimidine, pyridazine, pyran, piperidine, piperazine, morpholine, etc.
从所有上述描述中,对本领域技术人员显而易见的是,其名称是复合名称的任意基团,例如“芳基氨基”,应该指的是常规地从其衍生的部分例如从被芳基取代的氨基来构建,其中芳基如上文所定义。From all of the above description, it will be apparent to those skilled in the art that any group whose name is a compound name, such as "arylamino", should refer to the moiety from which it is conventionally derived, such as from aryl substituted amino to construct, wherein aryl is as defined above.
同样,任意术语例如烷硫基、烷基氨基、二烷基氨基、烷氧基羰基、烷氧基羰基氨基、杂环基羰基、杂环基羰基氨基、环烷基氧基羰基等包括基团,其中烷基、烷氧基、芳基、C3-C7环烷基和杂环基部分如上文所定义。Likewise, any term such as alkylthio, alkylamino, dialkylamino, alkoxycarbonyl, alkoxycarbonylamino, heterocyclylcarbonyl, heterocyclylcarbonylamino, cycloalkyloxycarbonyl, and the like includes groups , wherein the alkyl, alkoxy, aryl, C3 - C7cycloalkyl and heterocyclyl moieties are as defined above.
如本文所使用,除非另外说明,术语“前药”是指可以在生物学条件(体外或体内)下水解、氧化或进行其他反应以提供本发明的化合物的衍生物。前药仅在生物学条件下经过该反应成为活性化合物,或者它们在它们不反应的形式中具有活性。通常可以使用公知的方法制备前药,例如1Burger's Medicinal Chemistry and Drug Discovery(1995)172-178,949-982(Manfred E.Wolff编,第5版)中描述的那些方法。As used herein, and unless otherwise specified, the term "prodrug" refers to a derivative that can be hydrolyzed, oxidized, or otherwise reacted under biological conditions (in vitro or in vivo) to provide a compound of the present invention. Prodrugs only undergo this reaction under biological conditions to become the active compound, or they are active in their unreacted form. Prodrugs can generally be prepared using well-known methods, such as those described in 1 Burger's Medicinal Chemistry and Drug Discovery (1995) 172-178, 949-982 (eds. Manfred E. Wolff, 5th ed.).
药学上可以接受的盐可使用本领域熟知的标准程序获得,例如,通过将足量的碱性化合物和提供药学上可以接受的阴离子的合适的酸反应。Pharmaceutically acceptable salts can be obtained using standard procedures well known in the art, eg, by reacting a sufficient amount of a basic compound with a suitable acid to provide a pharmaceutically acceptable anion.
本文使用的术语“治疗”一般是指获得需要的药理和/或生理效应。该效应根据完全或部分地预防疾病或其症状,可以是预防性的;和/或根据部分或完全稳定或治愈疾病和/或由于疾病产生的副作用,可以是治疗性的。本文使用的“治疗”涵盖了对患者疾病的任何治疗,包括:(a)预防易感染疾病或症状但还没诊断出患病的患者所发生的疾病或症状;(b)抑制疾病的症状,即阻止其发展;或(c)缓解疾病的症状,即,导致疾病或症状退化。The term "treating" as used herein generally refers to obtaining a desired pharmacological and/or physiological effect. The effect may be prophylactic in terms of complete or partial prevention of the disease or its symptoms; and/or therapeutic in terms of partial or complete stabilization or cure of the disease and/or side effects due to the disease. "Treatment" as used herein encompasses any treatment of a disease in a patient, including: (a) prevention of disease or symptoms in a patient susceptible to a disease or condition but not yet diagnosed; (b) suppression of symptoms of disease, That is, preventing its development; or (c) alleviating the symptoms of the disease, ie, causing the disease or symptoms to regress.
按照本发明的一种具体技术方案,所述化合物、其立体异构体、其前药、或者其药学上可接受的盐或药学上可接受的溶剂合物,其中所述化合物为下面实施例中所述化合物之一。According to a specific technical solution of the present invention, the compound, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate, wherein the compound is the following example one of the compounds described in.
另一方面,本发明提供了一种药物组合物,其包含上述任一技术方案所述的化合物、其立体异构体、其前药、或者其药学上可接受的盐或药学上可接受的溶剂合物,和药学上可接受的载体、稀释剂或赋形剂。On the other hand, the present invention provides a pharmaceutical composition comprising the compound described in any of the above technical solutions, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable Solvates, and pharmaceutically acceptable carriers, diluents or excipients.
制备各种含有一定量的活性成分的药物组合物的方法是已知的,或根据本发明的公开内容对于本领域技术人员是显而易见的。如Remington’s Pharmaceutical Sciences,Martin,E.W.,ed.,Mack Publishing Company,19th ed.(1995)所述,制备所述药物组合物的方法包括掺入适当的药学赋形剂、载体、稀释剂等。Methods of preparing various pharmaceutical compositions containing amounts of active ingredients are known, or will be apparent to those skilled in the art in light of the present disclosure. Methods of preparing such pharmaceutical compositions include incorporating suitable pharmaceutical excipients, carriers, diluents, and the like, as described in Remington's Pharmaceutical Sciences, Martin, E.W., ed., Mack Publishing Company, 19th ed. (1995).
以已知的方法制造本发明的药物制剂,包括常规的混合、溶解或冻干方法。本发明的化合物可以制成药物组合物,并向患者以适于选定的施用方式的各种途径施用,例如,口服或肠胃外(通过静脉内、肌内、局部或皮下途径)。The pharmaceutical formulations of the present invention are manufactured by known methods, including conventional mixing, dissolving or lyophilization methods. The compounds of the present invention can be formulated into pharmaceutical compositions and administered to a patient by various routes suitable for the chosen mode of administration, eg, orally or parenterally (by intravenous, intramuscular, topical or subcutaneous routes).
因此,本发明的化合物结合药学上可以接受的载体(如惰性稀释剂或可同化的可食用的载体)可以全身施用,例如,口服。它们可以封闭在硬或软壳的明胶胶囊中,可以压为片剂。对于口服治疗施用,活性化合物可以结合一种或多种赋形剂,并以可吞咽的片剂、颊含片剂、含片、胶囊剂、酏剂、悬浮剂、糖浆、圆片等的形式使用。这种组合物和制剂应该包含至少0.1%的活性化合物。这种组合物和制剂的比例当然可以变化,可以占给定的单位剂型重量的大约1%至大约99%。在这种治疗有用的组合物中,活性化合物的量使得能够获得有效剂量水平。Thus, the compounds of the present invention can be administered systemically, eg, orally, in combination with a pharmaceutically acceptable carrier such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft shell gelatin capsules and can be compressed into tablets. For oral therapeutic administration, the active compound may be incorporated with one or more excipients and presented in the form of swallowable tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, and the like use. Such compositions and preparations should contain at least 0.1% active compound. The proportions of such compositions and formulations may, of course, vary and may range from about 1% to about 99% by weight of a given unit dosage form. In such therapeutically useful compositions, the active compound is in an amount such that an effective dosage level can be obtained.
片剂、含片、丸剂、胶囊剂等也可以包含:粘合剂,如黄蓍胶、阿拉伯胶、玉米淀粉或明胶;赋形剂,如磷酸氢二钙;崩解剂,如玉米淀粉、马铃薯淀粉、藻酸等;润滑剂,如硬脂酸镁;和甜味剂,如蔗糖、果糖、乳糖或阿司帕坦;或调味剂,如薄荷、冬青油或樱桃香味。当单位剂型是胶囊时,除了上面类型的材料,它还可以包含液体载体,如植物油或聚乙二醇。各种其他材料可以存在,作为包衣,或以其他方式改变固体单位剂型的物理形式。例如,片剂、丸剂或胶囊剂可以用明胶、蜡、虫胶或糖等包衣。糖浆或酏剂可以包含活性化合物,蔗糖或果糖作为甜味剂,对羟苯甲酸甲酯或对羟苯甲酸丙酯作为防腐剂,染料和调味剂(如樱桃香料或桔子香料)。当然,用于制备任何单位剂型的任何材料应该是药学上可以接受的且以应用的量基本上无毒。此外,活性化合物可以掺入缓释制剂和缓释装置中。Tablets, troches, pills, capsules, etc. may also contain: a binder, such as tragacanth, acacia, cornstarch, or gelatin; an excipient, such as dicalcium hydrogen phosphate; a disintegrant, such as cornstarch, Potato starch, alginic acid, etc.; lubricants, such as magnesium stearate; and sweeteners, such as sucrose, fructose, lactose, or aspartame; or flavoring agents, such as peppermint, oil of wintergreen, or cherry flavor. When the unit dosage form is a capsule, it can contain, in addition to materials of the above type, a liquid carrier such as a vegetable oil or polyethylene glycol. Various other materials may be present, as coatings, or otherwise alter the physical form of the solid unit dosage form. For example, tablets, pills or capsules may be coated with gelatin, wax, shellac or sugar and the like. A syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl or propyl paraben as a preservative, a dye and a flavoring (such as cherry flavor or orange flavor). Of course, any materials used in the preparation of any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts to be used. In addition, the active compounds can be incorporated into sustained release formulations and sustained release devices.
活性化合物也可以通过输注或注射来静脉内或腹膜内施用。可以制备活性化合物或其盐的水溶液,任选地混和无毒的表面活性剂。也可以制备在甘油、液体聚乙二醇、甘油三乙酸酯及其混合物以及油中的分散剂。在普通的储存和使用条件下,这些制剂包含防腐剂以防止微生物生长。The active compound may also be administered intravenously or intraperitoneally by infusion or injection. Aqueous solutions of the active compounds or salts thereof can be prepared, optionally mixed with nontoxic surfactants. Dispersions in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils can also be prepared. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
适于注射或输注的药物剂型可以包括包含适于无菌的可注射或可输注的溶液或分散剂的即时制剂的活性成分(任选封装在脂质体中)的无菌水溶液或分散剂或无菌粉末。在所有情况下,最终的剂型在生产和储存条件下必须是无菌的、液体的和稳定的。液体载体可以是溶剂或液体分散介质,包括,例如水、乙醇、多元醇(例如,甘油、丙二醇、液体聚乙二醇等)、植物油、无毒的甘油酯及其合适的混合物。可以维持合适的流动性,例如,通过脂质体的形成,通过在分散剂的情况下维持所需的粒子大小,或通过表面活性剂的使用。可以通过各种抗细菌剂和抗真菌剂(如对羟苯甲酸酯、氯丁醇、苯酚、山梨酸、硫柳汞等)产生预防微生物的作用。在许多情况下,优选包括等渗剂,如糖、缓冲剂或氯化钠。通过使用延缓吸收剂的组合物(例如,单硬脂酸铝和明胶)可以产生可注射的组合物的延长吸收。Pharmaceutical dosage forms suitable for injection or infusion can include sterile aqueous solutions or dispersions of the active ingredient (optionally encapsulated in liposomes) containing the active ingredient suitable for extemporaneous preparation in sterile injectable or infusible solutions or dispersions. or sterile powder. In all cases, the final dosage form must be sterile, liquid, and stable under the conditions of manufacture and storage. The liquid carrier can be a solvent or liquid dispersion medium containing, for example, water, ethanol, polyol (eg, glycerol, propylene glycol, liquid polyethylene glycol, and the like), vegetable oils, nontoxic glycerides, and suitable mixtures thereof. Proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the desired particle size in the case of dispersions, or by the use of surfactants. Prevention of microorganisms can be brought about by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases it is preferred to include isotonic agents such as sugars, buffers or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use of agents which delay absorption, for example, aluminum monostearate and gelatin.
通过将合适的溶剂中的需要量的活性化合物与需要的上面列举的各种其他成分结合,然后进行过滤灭菌,制备无菌可注射溶液。在用于制备无菌注射溶液的无菌粉末的情况下,优选的制备方法是真空干燥和冷冻干燥技术,这会产生活性成分加上任何另外需要的以前无菌过滤溶液中存在的成分的粉末。Sterile injectable solutions are prepared by incorporating the active compound in the required amount in an appropriate solvent with various of the other ingredients enumerated above as required, followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying techniques, which yield a powder of the active ingredient plus any additional required ingredients previously present in sterile-filtered solutions .
有用的固体载体包括粉碎的固体(如滑石、粘土、微晶纤维素、二氧化硅、氧化铝等)。有用的液体载体包括水、乙醇或乙二醇或水-乙醇/乙二醇混合物,本发明的化合物可以任选在无毒的表面活性剂的帮助下以有效含量溶解或分散在其中。可以加入佐剂(如香味)和另外的抗微生物剂来优化对于给定用途的性质。Useful solid carriers include pulverized solids (eg, talc, clays, microcrystalline cellulose, silica, alumina, and the like). Useful liquid carriers include water, ethanol or ethylene glycol, or water-ethanol/ethylene glycol mixtures, in which the compounds of the present invention may be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants. Adjuvants (eg, fragrances) and additional antimicrobial agents can be added to optimize properties for a given use.
增稠剂(如合成的聚合物、脂肪酸、脂肪酸盐和酯、脂肪醇、改性纤维素或改性无机材料)也可和液体载体用于形成可涂覆的糊剂、凝胶、软膏、肥皂等,直接用于使用者的皮肤上。Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified inorganic materials can also be used with liquid carriers to form coatable pastes, gels, ointments , soap, etc., directly on the user's skin.
化合物或其活性盐或衍生物的治疗需要量,不仅取决于选择的特定的盐,而且取决于施药方式、待治疗的疾病的本质和患者的年龄和状态,最终取决于在场医师或临床医生的决定。The therapeutically required amount of the compound or its active salt or derivative depends not only on the particular salt chosen, but also on the mode of administration, the nature of the disease to be treated and the age and status of the patient, and ultimately depends on the physician or clinician present decision.
上述制剂可以以单位剂型存在,该单位剂型是含有单位剂量的物理分散单元,适于向人体和其它哺乳动物体给药。单位剂型可以是胶囊或片剂,或是很多胶囊或片剂。根据所涉及的具体治疗,活性成分的单位剂量的量可以在大约0.1到大约1000毫克或更多之间进行变化或调整。The above formulations may be presented in unit dosage form, which are physically discrete units containing unitary dosages, suitable for administration to the human and other mammalian bodies. The unit dosage form can be a capsule or tablet, or a number of capsules or tablets. Depending on the particular treatment involved, the amount of active ingredient in a unit dose may vary or be adjusted from about 0.1 to about 1000 mg or more.
此外,还包括各种药物新剂型如乳脂质体、微球和纳米球的应用,如使用微粒分散体系包括聚合物胶束(polymeric micelles)、纳米乳(nanoemulsion)、亚微乳(submicroemuls微囊(microcapsule)、微球(microsphere)、脂质体(liposomes)和类脂囊泡(niosomes)(又称非离子表面活性剂囊泡)等制备的药剂。In addition, it also includes the application of various new pharmaceutical dosage forms such as milk liposomes, microspheres and nanospheres, such as the use of microparticle dispersion systems including polymeric micelles, nanoemulsion, submicroemuls Pharmaceutical preparations such as microcapsules, microspheres, liposomes and niosomes (also known as nonionic surfactant vesicles).
另一方面,本发明还提供了一种上述任一技术方案所述化合物的制备方法,包括下面步骤:On the other hand, the present invention also provides a preparation method of the compound described in any of the above-mentioned technical solutions, comprising the following steps:
X=Cl或BrX=Cl or Br
该反应的起始原料可以市购得到。Starting materials for this reaction are commercially available.
R'=H,Cl,BrR'=H,Cl,Br
反应条件:(a)碱性条件(如二异丙基乙基胺,三乙胺,碳酸钾等)或酸性条件(三氟乙酸,盐酸等)的取代反应;(b)酸性条件(三氟乙酸,盐酸等)或钯催化的胺化反应。Reaction conditions: (a) substitution reaction under basic conditions (such as diisopropylethylamine, triethylamine, potassium carbonate, etc.) or acidic conditions (trifluoroacetic acid, hydrochloric acid, etc.); (b) acidic conditions (trifluoroacetic acid, etc.) acetic acid, hydrochloric acid, etc.) or palladium-catalyzed amination reaction.
另一方面,本发明还提供了一种上述任一技术方案所述化合物、其立体异构体、其前药、或者其药学上可接受的盐或药学上可接受的溶剂合物在制备预防和治疗肿瘤的药物中的用途。优选地,其中所述肿瘤为渐变性大细胞淋巴瘤、炎性肌纤维母细胞瘤、非小细胞肺癌、成神经母细胞瘤、小细胞肺癌、肺腺癌、胰腺癌、乳腺癌、前列腺癌、肝癌、皮肤癌、上皮细胞癌、胃肠间质瘤、白血病、组织细胞性淋巴瘤、鼻咽癌中的任意一种;更优选地,其中所述肿瘤为渐变性大细胞淋巴瘤、炎性肌纤维母细胞瘤、非小细胞肺癌或成神经母细胞瘤。On the other hand, the present invention also provides a compound described in any of the above technical solutions, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate in the preparation of prevention and use in the drug for the treatment of tumors. Preferably, wherein the tumor is graded large cell lymphoma, inflammatory myofibroblastic tumor, non-small cell lung cancer, neuroblastoma, small cell lung cancer, lung adenocarcinoma, pancreatic cancer, breast cancer, prostate cancer, Any one of liver cancer, skin cancer, epithelial cell carcinoma, gastrointestinal stromal tumor, leukemia, histiocytic lymphoma, and nasopharyngeal carcinoma; more preferably, wherein the tumor is graded large cell lymphoma, inflammatory Myofibroblastic tumor, non-small cell lung cancer, or neuroblastoma.
具体实施方式Detailed ways
下面通过具体实施例详细描述本发明的实施方式,但是无论如何它们不能解释为对本发明的限制。Embodiments of the present invention will be described in detail below through specific examples, but they should not be construed as limiting the present invention in any way.
通用纯化和分析方法General Purification and Analysis Methods
在硅胶GF254预涂覆板(青岛海洋化工厂)上进行薄层色谱。在中压下经硅胶(300-400目,烟台芝黄务硅胶开发试剂厂)进行柱色谱分离或通过使用ISCO Combiflash Rf200快速纯化系统用预装的硅胶筒(ISCO或Welch)进行柱色谱分离。成分通过UV光和通过碘蒸气显影。当必要时,将化合物通过制备型HPLC制备经Waters Symmetry C18(19x50mm,5μm)柱或经Waters X Terra RP 18(30x 150mm,5μm)柱纯化,使用装配有996WatersPDA检测器的Waters制备型HPLC 600和Micromass mod.ZMD单四级质谱(电喷雾离子化,阳离子模式)。方法1:相A:0.1%TFA/MeOH 95/5;相B:MeOH/H2O 95/5。梯度:10至90%B进行8min,保持90%B 2min;流速20mL/min。方法2:相A:0.05%NH4OH/MeOH 95/5;相B:MeOH/H2O95/5。梯度:10至100%B进行8min,保持100%B 2min。流速20mL/min。Thin-layer chromatography was performed on silica gel GF254 precoated plates (Qingdao Ocean Chemical Factory). Column chromatography was performed on silica gel (300-400 mesh, Yantai Zhihuangwu Silica Gel Development Reagent Factory) at medium pressure or by prepacked silica cartridges (ISCO or Welch) using an ISCO Combiflash Rf200 rapid purification system. ingredients pass UV light and developed by iodine vapor. When necessary, compounds were purified by preparative HPLC on a Waters Symmetry C18 (19x50mm, 5μm) column or on a Waters X Terra RP 18 (30x 150mm, 5μm) column using a
将1H-NMR谱在DMSO-d6或CDCl3中经在600MHz操作的Bruker Avance 600谱仪(对于1H而言)进行记录。将残留溶剂信号用作参比化学位移以百万分率(ppm)进行报道且偶合常数(J)以Hz计。以下缩写用于峰裂分:s=单;br.s.=宽信号;d=双;t=三;m=多重;dd=双双。 1 H-NMR spectra were recorded in DMSO-d 6 or CDCl 3 on a
电喷雾(ESI)质谱经Finnigan LCQ离子阱获得。Electrospray (ESI) mass spectra were acquired on a Finnigan LCQ ion trap.
除非另外说明,所有最终化合物均是均质的(纯度不低于95%),如高效液相色谱(HPLC)所确定。用于评价化合物纯度的HPLC-UV-MS分析通过组合离子阱MS设备与HPLC系统SSP4000(Thermo Separation Products)来进行,所述HPLC系统装配有自动进样器LC Pal(CTC Analytics)和UV6000LP二极管阵列检测器(UV检测215-400nm)。用Xcalibur 1.2软件(Finnigan)进行设备控制、数据采集和处理。HPLC色谱法在室温和1mL/min流速下进行,其使用Waters X Terra RP 18柱(4.6x 50mm;3.5μm)。流动相A是乙酸铵5mM缓冲液(采用乙酸得到pH 5.5):乙腈90:10,流动相B乙酸铵5mM缓冲液(采用乙酸得到pH 5.5):乙腈10:90;梯度为0至100%B进行7分钟,然后在再平衡前保持100%B达2分钟。All final compounds were homogeneous (no less than 95% pure) as determined by high performance liquid chromatography (HPLC) unless otherwise stated. HPLC-UV-MS analysis for evaluating compound purity was performed by combining ion trap MS equipment with HPLC system SSP4000 (Thermo Separation Products) equipped with autosampler LC Pal (CTC Analytics) and UV6000LP diode array Detector (UV detection 215-400 nm). Device control, data acquisition and processing were performed with Xcalibur 1.2 software (Finnigan). HPLC chromatography was performed at room temperature and a flow rate of 1 mL/min using a Waters X Terra RP 18 column (4.6 x 50 mm; 3.5 μm). Mobile phase A was ammonium acetate 5mM buffer (using acetic acid to give pH 5.5):acetonitrile 90:10, mobile phase B ammonium acetate 5mM buffer (using acetic acid to give pH 5.5):acetonitrile 10:90; gradient 0 to 100% B This was done for 7 minutes, then 100% B was held for 2 minutes before re-equilibration.
试剂纯化参考Purification of Laboratory Chemicals(Perrin,D.D.,Armarego,W.L.F.and Perrins Eds,D.R.;Pergamon Press:Oxford,1980)一书进行。石油醚是60-90℃馏分、乙酸乙酯、甲醇、二氯甲烷均为分析纯。Reagent purification was carried out with reference to the book Purification of Laboratory Chemicals (Perrin, D.D., Armarego, W.L.F. and Perrins Eds, D.R.; Pergamon Press: Oxford, 1980). Petroleum ether is a 60-90°C fraction, and ethyl acetate, methanol, and dichloromethane are all analytically pure.
上述通式化合物分成几类合成制备。Compounds of the general formula above are divided into several classes of synthetic preparations.
化合物I的通式General formula of compound I
实施例1Example 1
化合物IA的合成通式Synthetic formula of compound IA
化合物3的制备Preparation of compound 3
将化合物2(200mg,1.17mmol)溶于N,N-二甲基甲酰胺中(4mL),在冰浴条件下加入氢化钠(93.6mg,2.34mmol)搅拌5-10min,然后加入化合物1(240.0mg,1.17mmol),在室温下搅拌1.0h(TLC跟踪)后停止反应。向体系中加入冰水淬灭氢化钠,加入乙酸乙酯并分液,有机相用饱和氯化钠溶液洗涤两次,无水硫酸钠干燥,浓缩后经硅胶柱层析(石油醚/乙酸乙酯=5/1)得化合物3(固体,270.0mg,产率为79.5%),直接用于下一步反应。Compound 2 (200 mg, 1.17 mmol) was dissolved in N,N-dimethylformamide (4 mL), sodium hydride (93.6 mg, 2.34 mmol) was added in an ice bath and stirred for 5-10 min, and then compound 1 ( 240.0 mg, 1.17 mmol), quenched after stirring at room temperature for 1.0 h (TLC tracking). Ice water was added to the system to quench sodium hydride, ethyl acetate was added and the solution was separated. The organic phase was washed twice with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated and subjected to silica gel column chromatography (petroleum ether/ethyl acetate). ester=5/1) to obtain compound 3 (solid, 270.0 mg, yield 79.5%), which was directly used in the next reaction.
MS(ESI)m/z:340[M+H]+.MS(ESI) m/z: 340[M+H] + .
化合物IA的制备Preparation of Compound IA
方法A:Method A:
将化合物3(30.0mg,0.09mmol)、芳胺(0.072mmol)溶于1mL叔丁醇中,再向该溶液中加入2-二环己基膦-2,4,6-三异丙基联苯(7.7mg,0.016mmol),三(二亚苄基丙酮)二钯(9.9mg,0.011mmol),碳酸钾(37mg,0.27mmol),在氮气的保护下,将所得反应液置于预热至110℃的油浴中加热搅拌,至芳胺反应完全(LC-MS和TLC跟踪)停止反应。向反应液中加甲醇和二氯甲烷,将体系过滤,浓缩后经硅胶柱层析(二氯甲烷/甲醇)得化合物IA。Compound 3 (30.0 mg, 0.09 mmol) and arylamine (0.072 mmol) were dissolved in 1 mL of tert-butanol, and 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl was added to the solution. (7.7 mg, 0.016 mmol), tris(dibenzylideneacetone)dipalladium (9.9 mg, 0.011 mmol), potassium carbonate (37 mg, 0.27 mmol), under the protection of nitrogen, the resulting reaction solution was placed preheated to The reaction was stopped by heating and stirring in an oil bath at 110° C. until the reaction of the aromatic amine was complete (tracked by LC-MS and TLC). Methanol and dichloromethane were added to the reaction solution, the system was filtered, concentrated, and subjected to silica gel column chromatography (dichloromethane/methanol) to obtain compound IA.
方法B:Method B:
将化合物3(30.0mg,0.09mmol)、芳胺(0.072mmol)溶于1mL叔丁醇中,再向该溶液中加入2-二环己基膦-2,4,6-三异丙基联苯(7.7mg,0.016mmol),三(二亚苄基丙酮)二钯(9.9mg,0.011mmol),碳酸钾(37mg,0.27mmol),在氮气的保护下,将所得反应液置于预热至110℃的油浴中加热搅拌,至芳胺反应完全(LC-MS和TLC跟踪)停止反应。向反应液中加甲醇和二氯甲烷,将体系过滤,浓缩后经反相制备型HPLC纯化(以含0.35%三氟乙酸的水溶液和甲醇为流动相),经真空浓缩得化合物IA。Compound 3 (30.0 mg, 0.09 mmol) and arylamine (0.072 mmol) were dissolved in 1 mL of tert-butanol, and 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl was added to the solution. (7.7 mg, 0.016 mmol), tris(dibenzylideneacetone)dipalladium (9.9 mg, 0.011 mmol), potassium carbonate (37 mg, 0.27 mmol), under the protection of nitrogen, the resulting reaction solution was placed preheated to The reaction was stopped by heating and stirring in an oil bath at 110° C. until the reaction of the aromatic amine was complete (tracked by LC-MS and TLC). Methanol and dichloromethane were added to the reaction solution, and the system was filtered, concentrated and purified by reverse-phase preparative HPLC (using an aqueous solution containing 0.35% trifluoroacetic acid and methanol as mobile phases), and concentrated in vacuo to obtain compound IA.
化合物IB、IC均可使用类似的方法合成。Compounds IB and IC can be synthesized using similar methods.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表1.化合物IA—IC结构及表征Table 1. Structure and Characterization of Compounds IA-IC
实施例2Example 2
化合物ID的合成通式Synthetic formula of compound ID
化合物5的制备Preparation of compound 5
将化合物1(205mg,1.00mmol)、化合物4(151mg,1.00mmol)溶于5mL叔丁醇中,再向该溶液中加入2-二环己基膦-2,4,6-三异丙基联苯(56mg,0.12mmol),三(二亚苄基丙酮)二钯(37mg,0.04mmol),碳酸钾(415mg,3.00mmol),在氮气的保护下,将所得反应液置于预热至110℃的油浴中加热搅拌,至化合物1反应完全(LC-MS和TLC跟踪)。向反应液中加甲醇和二氯甲烷,将体系过滤,滤液浓缩后再用二氯甲烷稀释,饱和氯化钠溶液洗涤两次,无水硫酸钠干燥,浓缩后经硅胶柱层析(二氯甲烷/氨甲醇=10/1)得化合物5(白色固体,293.5mg,产率为92.0%),直接用于下一步反应。Compound 1 (205 mg, 1.00 mmol) and compound 4 (151 mg, 1.00 mmol) were dissolved in 5 mL of tert-butanol, and 2-dicyclohexylphosphine-2,4,6-triisopropyl bicarbonate was added to the solution. Benzene (56 mg, 0.12 mmol), tris(dibenzylideneacetone)dipalladium (37 mg, 0.04 mmol), potassium carbonate (415 mg, 3.00 mmol), under the protection of nitrogen, the resulting reaction solution was preheated to 110 The mixture was heated and stirred in an oil bath at °C until the reaction of
MS(ESI)m/z:320[M+H]+ MS(ESI)m/z:320[M+H] +
化合物ID的制备Preparation of Compound ID
方法A:Method A:
将化合物5(31.8mg,0.10mmol)、芳胺(0.09mmol)溶于1mL叔丁醇中,再向该溶液中加入2-二环己基膦-2,4,6-三异丙基联苯(0.018mmol),三(二亚苄基丙酮)二钯(0.012mmol),碳酸钾(0.30mmol),在氮气的保护下,将所得反应液置于预热至110℃的油浴中加热搅拌,至化合物5反应完全后(LC-MS和TLC跟踪)停止反应。向反应液中加甲醇和二氯甲烷,将体系过滤,浓缩后经硅胶柱层析(二氯甲烷/甲醇)得化合物ID。Compound 5 (31.8 mg, 0.10 mmol) and arylamine (0.09 mmol) were dissolved in 1 mL of tert-butanol, and 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl was added to the solution. (0.018mmol), tris(dibenzylideneacetone)dipalladium (0.012mmol), potassium carbonate (0.30mmol), under the protection of nitrogen, the resulting reaction solution was placed in an oil bath preheated to 110°C with heating and stirring , the reaction was stopped when the reaction of compound 5 was completed (LC-MS and TLC tracking). Methanol and dichloromethane were added to the reaction solution, the system was filtered, concentrated, and subjected to silica gel column chromatography (dichloromethane/methanol) to obtain compound ID.
方法B:Method B:
将化合物5(31.8mg,0.10mmol)、芳胺(0.09mmol)溶于1mL叔丁醇中,再向该溶液中加入2-二环己基膦-2,4,6-三异丙基联苯(0.018mmol),三(二亚苄基丙酮)二钯(0.012mmol),碳酸钾(0.30mmol),在氮气的保护下,将所得反应液置于预热至110℃的油浴中加热搅拌,至化合物5反应完全后(LC-MS和TLC跟踪)停止反应。向反应液中加甲醇和二氯甲烷,将体系过滤,浓缩后经反相制备型HPLC纯化(以含0.35%三氟乙酸的水溶液和甲醇为流动相),经真空浓缩得化合物ID。Compound 5 (31.8 mg, 0.10 mmol) and arylamine (0.09 mmol) were dissolved in 1 mL of tert-butanol, and 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl was added to the solution. (0.018mmol), tris(dibenzylideneacetone)dipalladium (0.012mmol), potassium carbonate (0.30mmol), under the protection of nitrogen, the resulting reaction solution was placed in an oil bath preheated to 110°C with heating and stirring , the reaction was stopped when the reaction of compound 5 was completed (LC-MS and TLC tracking). Methanol and dichloromethane were added to the reaction solution, and the system was filtered, concentrated and purified by reverse-phase preparative HPLC (using an aqueous solution containing 0.35% trifluoroacetic acid and methanol as mobile phases), and concentrated in vacuo to obtain compound ID.
化合物IE、IF、IG、IH、II、IJ、IK均可使用类似的方法合成。Compounds IE, IF, IG, IH, II, IJ, IK can all be synthesized using similar methods.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表2.化合物ID—IK结构及表征Table 2. Compound ID—IK structure and characterization
实施例3Example 3
化合物IL的合成通式Synthetic formula of compound IL
化合物7的制备Preparation of compound 7
将化合物6(185.2mg,1.0mmol)、三乙基胺(0.418mL,3.0mmol)溶于N,N-二甲基甲酰胺中(1.5mL),室温搅拌10min后滴加到化合物1(205.0mg,1.0mmol)的N,N-二甲基甲酰胺(1.5mL)溶液中,在室温下搅拌过夜,(TLC跟踪)停止反应。向体系加入乙酸乙酯、水萃取,有机相由饱和氯化钠溶液洗涤,无水硫酸钠干燥,浓缩后经硅胶柱层析(石油醚/乙酸乙酯=2/1)得化合物7(固体,120.0mg,产率为33.9%),直接用于下一步反应。Compound 6 (185.2 mg, 1.0 mmol) and triethylamine (0.418 mL, 3.0 mmol) were dissolved in N,N-dimethylformamide (1.5 mL), stirred at room temperature for 10 min, and added dropwise to compound 1 (205.0 mg, 1.0 mmol) in N,N-dimethylformamide (1.5 mL), stirred at room temperature overnight, (TLC tracking) to stop the reaction. Ethyl acetate was added to the system, water was extracted, the organic phase was washed with saturated sodium chloride solution, dried over anhydrous sodium sulfate, concentrated and subjected to silica gel column chromatography (petroleum ether/ethyl acetate=2/1) to obtain compound 7 (solid , 120.0 mg, 33.9% yield), which was directly used in the next reaction.
MS(ESI)m/z:354[M+H]+ MS(ESI)m/z:354[M+H] +
化合物IL的制备Preparation of compound IL
方法A:Method A:
将化合物7(35.3mg,0.10mmol)、芳胺(0.09mmol)溶于1mL叔丁醇中,再向该溶液中加入2-二环己基膦-2,4,6-三异丙基联苯(0.018mmol),三(二亚苄基丙酮)二钯(0.012mmol),碳酸钾(0.30mmol),在氮气的保护下,将所得反应液置于预热至110℃的油浴中加热搅拌,至化合物7反应完全后(LC-MS和TLC跟踪)停止反应。向反应液中加甲醇和二氯甲烷,将体系过滤,浓缩后经硅胶柱层析(二氯甲烷/甲醇)得化合物IL。Compound 7 (35.3 mg, 0.10 mmol) and arylamine (0.09 mmol) were dissolved in 1 mL of tert-butanol, and 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl was added to the solution. (0.018mmol), tris(dibenzylideneacetone)dipalladium (0.012mmol), potassium carbonate (0.30mmol), under the protection of nitrogen, the resulting reaction solution was placed in an oil bath preheated to 110°C with heating and stirring , the reaction was stopped when the reaction of compound 7 was completed (LC-MS and TLC tracking). Methanol and dichloromethane were added to the reaction solution, the system was filtered, concentrated, and subjected to silica gel column chromatography (dichloromethane/methanol) to obtain compound IL.
方法B:Method B:
将化合物7(35.3mg,0.10mmol)、芳胺(0.09mmol)溶于1mL叔丁醇中,再向该溶液中加入2-二环己基膦-2,4,6-三异丙基联苯(0.018mmol),三(二亚苄基丙酮)二钯(0.012mmol),碳酸钾(0.30mmol),在氮气的保护下,将所得反应液置于预热至110℃的油浴中加热搅拌,至化合物7反应完全后(LC-MS和TLC跟踪)停止反应。向反应液中加甲醇和二氯甲烷,将体系过滤,浓缩后经反相制备型HPLC纯化(以含0.35%三氟乙酸的水溶液和甲醇为流动相),经真空浓缩得化合物IL。Compound 7 (35.3 mg, 0.10 mmol) and arylamine (0.09 mmol) were dissolved in 1 mL of tert-butanol, and 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl was added to the solution. (0.018mmol), tris(dibenzylideneacetone)dipalladium (0.012mmol), potassium carbonate (0.30mmol), under the protection of nitrogen, the resulting reaction solution was placed in an oil bath preheated to 110°C with heating and stirring , the reaction was stopped when the reaction of compound 7 was completed (LC-MS and TLC tracking). Methanol and dichloromethane were added to the reaction solution, and the system was filtered, concentrated and purified by reverse-phase preparative HPLC (using an aqueous solution containing 0.35% trifluoroacetic acid and methanol as mobile phases), and concentrated in vacuo to obtain compound IL.
化合物IM可使用类似的方法合成。Compound IM can be synthesized using a similar method.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表3.化合物IL—IM结构及表征Table 3. Structure and characterization of compound IL-IM
实施例4Example 4
化合物IN的合成通式Synthetic formula of compound IN
化合物9的制备Preparation of compound 9
将化合物1(500mg,2.44mmol)、化合物8(0.09mmol)溶于20mL叔丁醇中,再向该溶液中加入2-二环己基膦-2,4,6-三异丙基联苯(135mg,0.17mmol),三(二亚苄基丙酮)二钯(90mg,0.06mmol),碳酸钾(1.01g,3.0mmol),在氮气的保护下,将所得反应液置于预热至45℃的油浴中加热搅拌,至化合物1反应完全后(LC-MS和TLC跟踪)停止反应。将体系过滤并用甲醇洗涤,滤液浓缩后经硅胶柱层析(二氯甲烷/胺甲醇=5/1)得化合物9(黄色固体,540mg,产率为65.7%),直接用于下一步反应。Compound 1 (500 mg, 2.44 mmol) and compound 8 (0.09 mmol) were dissolved in 20 mL of tert-butanol, and 2-dicyclohexylphosphine-2,4,6-triisopropylbiphenyl ( 135mg, 0.17mmol), tris(dibenzylideneacetone)dipalladium (90mg, 0.06mmol), potassium carbonate (1.01g, 3.0mmol), under the protection of nitrogen, the resulting reaction solution was preheated to 45°C The reaction was stopped after heating and stirring in the oil bath of the compound 1 (LC-MS and TLC tracking) after the completion of the reaction of
MS(ESI)m/z:337[M+H]+ MS(ESI)m/z:337[M+H] +
化合物IN的制备Preparation of compound IN
将化合物9(50mg,0.15mmol)、芳胺(0.13mmol)溶于1mL叔丁醇中,再向该溶液中加入三氟乙酸(35μL,0.45mmol)。所得反应液置于预热至110℃的油浴中加热搅拌,至芳胺反应完全(LC-MS和TLC跟踪)。停止反应,浓缩,经反相制备型HPLC纯化(以含0.35%三氟乙酸的水溶液和甲醇为流动相),经真空浓缩得化合物IN。Compound 9 (50 mg, 0.15 mmol) and arylamine (0.13 mmol) were dissolved in 1 mL of tert-butanol, and to the solution was added trifluoroacetic acid (35 μL, 0.45 mmol). The resulting reaction solution was placed in an oil bath preheated to 110° C. with heating and stirring until the reaction of the aromatic amine was complete (tracked by LC-MS and TLC). The reaction was stopped, concentrated, purified by reverse-phase preparative HPLC (with 0.35% trifluoroacetic acid-containing aqueous solution and methanol as mobile phases), and concentrated in vacuo to obtain compound IN.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表4.化合物IN结构及表征Table 4. Structure and Characterization of Compound IN
实施例5Example 5
化合物IOCompound IO
化合物IO使用IA类似的方法合成。Compound IO was synthesized using an analogous method for IA.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表5.化合物IO结构及表征Table 5. Structure and Characterization of Compound IO
实施例6Example 6
化合物IP,IQCompound IP,IQ
化合物IP、IQ使用IA类似的方法合成。Compounds IP, IQ were synthesized using a similar method for IA.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表6.化合物IP、IQ结构及表征Table 6. Compound IP, IQ structure and characterization
实施例7Example 7
化合物IR,ISCompound IR, IS
化合物IR、IS使用IA类似的方法合成。Compounds IR and IS were synthesized using a similar method to IA.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表7.化合物IR、IS结构及表征Table 7. Compound IR, IS structure and characterization
实施例8Example 8
化合物ITCompound IT
化合物IT使用IA类似的方法合成。Compound IT was synthesized using a similar method to IA.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表8.化合物IT结构及表征Table 8. Compound IT structure and characterization
实施例9Example 9
化合物IUCompound IU
化合物IU使用IA类似的方法合成。Compound IU was synthesized using an analogous method for IA.
下表列出了具体化合物及结构鉴定数据。The following table lists specific compounds and structural identification data.
表9.化合物IU结构及表征Table 9. Compound IU structure and characterization
试验例Test example
生物活性测试:Biological activity test:
化合物对激酶稳转细胞系的生长抑制活性Growth Inhibitory Activity of Compounds on Kinase-Stable Cell Lines
化合物对激酶ALK的活性通过其抑制激酶稳转细胞系EML4-ALK-BaF3,EML4-ALK(L1196M)-BaF3,NPM-ALK-BaF3,和野生型BaF3的生长进行评价(Proc.Natl.Acad.Sci.U SA.,2006,103,3153-8.)。激酶稳转的细胞系EML4-ALK-BaF3,EML4-ALK(L1196M)-BaF3和NPM-ALK-BaF3的生长依赖其激酶活性,化合物若能抑制激酶ALK自身活性或ALK信号通路的活性就能抑制其稳转BaF3细胞的生长。而野生型BaF3的细胞生长不依赖ALK和ALK信号通路的活性,测定化合物对野生型BaF3细胞的生长的影响可以评价其广谱毒性。因此化合物对野生型BaF3和激酶稳转的EML4-ALK-BaF3,EML4-ALK(L1196M)-BaF3,NPM-ALK-BaF3间IC50的比值越大表明具有更好的靶向性。The activity of compounds against the kinase ALK was evaluated by their inhibition of the growth of the kinase-stable cell lines EML4-ALK-BaF3, EML4-ALK(L1196M)-BaF3, NPM-ALK-BaF3, and wild-type BaF3 (Proc.Natl.Acad. Sci. U SA., 2006, 103, 3153-8.). The growth of the kinase-stable cell lines EML4-ALK-BaF3, EML4-ALK(L1196M)-BaF3 and NPM-ALK-BaF3 depends on their kinase activity. Compounds that inhibit the activity of the kinase ALK itself or the activity of the ALK signaling pathway can inhibit It stably transduced the growth of BaF3 cells. While the growth of wild-type BaF3 cells does not depend on the activity of ALK and ALK signaling pathways, measuring the effect of compounds on the growth of wild-type BaF3 cells can evaluate its broad-spectrum toxicity. Therefore, the greater the ratio of IC50 between wild-type BaF3 and kinase-stabilized EML4-ALK-BaF3, EML4-ALK(L1196M)-BaF3, and NPM-ALK-BaF3 indicates better targeting.
具体试验方法如下:The specific test methods are as follows:
1)培养基:DMEM(Dulbecco's modified eagle medium)或RPMI1640(含10%胎牛血清,100μg/mL氨苄青霉素,100μg/mL链霉素)。1) Medium: DMEM (Dulbecco's modified eagle medium) or RPMI1640 (containing 10% fetal bovine serum, 100 μg/mL ampicillin, 100 μg/mL streptomycin).
2)试剂:MTS反应液(含2mg/mL的MTS[3-(4,5-二甲基噻唑-2-基)-5-(3-羧基甲氧基苯基)-2-(4-磺苯基)-2H-四唑,内盐](3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,inner salt);100μg/mL的PES(phenazine methosulfate))。2) Reagent: MTS reaction solution (containing 2 mg/mL of MTS[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4- Sulfophenyl)-2H-tetrazolium,inner salt](3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,inner salt ); 100 μg/mL of PES (phenazine methosulfate)).
3)化合物测试:将激酶稳转的细胞(EML4-ALK-BaF3,或EML4-ALK(L1196M)-BaF3或NPM-ALK-BaF3)(2×104个/孔)接入96-孔培养板,细胞液体积为90μL,然后加入各梯度浓度化合物10μL(最高浓度为10μM,依次按1/3逐级稀释,共设置8个浓度点,体系中含0.1%DMSO(二甲基亚砜))。混匀化合物的细胞板置于细胞培养箱中(37℃;5%CO2)培养48h,再加入20μL的MTS反应液,混匀后置于细胞培养箱中(37℃;5%CO2)孵育1-4hr;采用酶标仪(VARIOSKAN FLASH,Thermo)测量490nm波长下的OD值。每组实验设置三个平行,以终浓度为0.1%DMSO为阴性对照,以不含细胞及化合物的培养基为空白对照。细胞生长抑制率由如下公式计算:3) Compound test: cells stably transduced with kinases (EML4-ALK-BaF3, or EML4-ALK(L1196M)-BaF3 or NPM-ALK-BaF3) (2×10 4 cells/well) were placed in a 96-well culture plate , the volume of the cell fluid is 90 μL, and then 10 μL of each gradient concentration compound is added (the highest concentration is 10 μM, which is successively diluted by 1/3, a total of 8 concentration points are set, and the system contains 0.1% DMSO (dimethyl sulfoxide)) . The cell plate with the mixed compound was placed in a cell incubator (37°C; 5% CO 2 ) for 48 hours, then 20 μL of MTS reaction solution was added, and the mixture was placed in a cell incubator (37° C; 5% CO 2 ). Incubate for 1-4 hr; use a microplate reader (VARIOSKAN FLASH, Thermo) to measure the OD value at a wavelength of 490 nm. Three parallels were set for each group of experiments, with the final concentration of 0.1% DMSO as the negative control, and the medium without cells and compounds as the blank control. The cell growth inhibition rate was calculated by the following formula:
细胞抑制率%=1-(OD实验组-OD空白组)/(OD阴性组-OD空白组)*100%Cell inhibition rate%=1-(OD experimental group-OD blank group)/(OD negative group-OD blank group)*100%
4)IC50值计算:根据测量的细胞生长抑制率利用GradPad Prism 5软件计算化合物作用于细胞生长的半抑制浓度。4) IC 50 value calculation: According to the measured cell growth inhibition rate, GradPad Prism 5 software was used to calculate the half-inhibitory concentration of the compound acting on cell growth.
表10.化合物I系列对激酶稳转细胞系的生长抑制活性Table 10. Growth inhibitory activity of compound I series on kinase stable cell lines
*数值代表在化合物浓度为3.3μM下对细胞的生长抑制率,Crizotinib(克唑替尼)做为阳性对照,ND指未测定。*Values represent the growth inhibition rate of cells at a compound concentration of 3.3 μM, Crizotinib was used as a positive control, ND means not determined.
表11.化合物IB-1对其它ALK点突变稳转的BaF3细胞的生长抑制活性(IC50/nM)Table 11. Growth inhibitory activity ( IC50 /nM) of compound IB-1 on BaF3 cells stably transduced with other ALK point mutations
化合物对肿瘤细胞的生长抑制活性Growth Inhibitory Activity of Compounds on Tumor Cells
若测试的肿瘤细胞为悬浮细胞,参照上述(1)的方法进行测定。If the tumor cells to be tested are suspension cells, the measurement is carried out according to the method of (1) above.
若测试的肿瘤细胞为贴壁细胞,以1000-10000细胞/孔加入96-孔培养板中,孵育至贴壁后加化合物。其它参照上述(1)的方法进行。If the tested tumor cells are adherent cells, add 1000-10000 cells/well to a 96-well culture plate, incubate until adherent, and then add compounds. Others are carried out with reference to the method of (1) above.
化合物IB-1对激酶ALK阳性的肺癌细胞株H3122和渐变性大细胞淋巴瘤Karpas-299均有很好的抑制活性。由以上活性数据可以看出,对于活性较好的化合物均具有较好的靶向选择性。Compound IB-1 has good inhibitory activity on ALK-positive lung cancer cell line H3122 and graded large cell lymphoma Karpas-299. It can be seen from the above activity data that the compounds with better activity have better target selectivity.
表12.化合物IB-1对肿瘤细胞和BaF3细胞的生长抑制活性Table 12. Growth inhibitory activity of compound IB-1 on tumor cells and BaF3 cells
*Crizotinib(克唑替尼)做为阳性对照,ND指未测定。*Crizotinib was used as a positive control, ND means not determined.
体内药效评价In vivo efficacy evaluation
1.化合物IB-1在EML4-ALK(G1202R)-Ba/F3裸鼠异种移植瘤模型中显著抑制肿瘤生长(图1)1. Compound IB-1 significantly inhibited tumor growth in EML4-ALK(G1202R)-Ba/F3 nude mouse xenograft tumor model (Figure 1)
本次试验动物选用BALB/c(nu/nu)裸鼠,雌雄各半,4-6周龄,体重约18±2g,SPF级环境饲养,严格无菌操作。实验动物提前1周适应实验环境,自由取食饮水,保持12h昼夜节律。The experimental animals were BALB/c (nu/nu) nude mice, half male and half male, 4-6 weeks old, weighing about 18±2g, raised in an SPF environment, and strictly operated aseptically. The experimental animals were acclimated to the experimental environment one week in advance, had free access to food and water, and maintained a 12-h circadian rhythm.
实验所用EML4-ALK(G1202R)-Ba/F3细胞选用PRMI-1640培养液加入10%胎牛血清培养,细胞放置于37℃,5%CO2培养箱环境。The EML4-ALK(G1202R)-Ba/F3 cells used in the experiment were cultured with PRMI-1640 medium and 10% fetal bovine serum, and the cells were placed in a 37°C, 5% CO 2 incubator environment.
细胞接种法建立肿瘤裸鼠皮下移植模型:过滤收集对数生长期细胞,离心后用PBS清洗,用PRMI-1640培养液重悬为单细胞悬液,按每只裸鼠1×106/200μL细胞量。用1mL注射器(4.5号针头)在裸鼠右前腋附近皮下注射细胞悬液。当荷瘤小鼠肿瘤长到可测量大小时开始每日测量计算瘤体积,在肿瘤体积达到150mm3左右时随机将小鼠进行分组,每组8只,共三组,分组当日开始给药。给药组分为IB-1 60mg/kg(1次/天),40mg/kg(2次/天,bid),口服给药,连续给药10天,阴性对照组给等量溶剂。试验期间每天测定动物体重和肿瘤大小,每日观察记录小鼠状态,最后一次给药6h后用5%的水合氯醛麻醉处死小鼠,取肿瘤,称重并拍照记录。肿瘤体积(TumorVolume,TV)的计算公式为:TV=1/2×a×b2,其中a,b分别表示肿瘤长径和短径。The tumor nude mouse subcutaneous transplantation model was established by the cell inoculation method: the cells in the logarithmic growth phase were collected by filtration, washed with PBS after centrifugation, and resuspended in PRMI -1640 medium to form a single cell suspension. amount of cells. The cell suspension was subcutaneously injected near the right anterior axilla of nude mice with a 1 mL syringe (4.5 gauge needle). When the tumor of the tumor-bearing mice grew to a measurable size, the tumor volume was measured and calculated every day. When the tumor volume reached about 150 mm 3 , the mice were randomly divided into groups, with 8 mice in each group, for a total of three groups, and the administration began on the day of grouping. The administration components were IB-1 60 mg/kg (1 time/day), 40 mg/kg (2 times/day, bid), orally administered for 10 consecutive days, and the negative control group was given the same amount of solvent. During the experiment, the body weight and tumor size of the animals were measured every day, and the state of the mice was observed and recorded every day. The mice were anesthetized with 5% chloral hydrate 6 hours after the last administration, and the tumors were taken, weighed, and photographed for recording. The calculation formula of tumor volume (Tumor Volume, TV) is: TV=1/2×a×b 2 , where a and b represent the long and short diameters of the tumor, respectively.
如图1所示,化合物IB-1在EML4-ALK(G1202R)-Ba/F3裸鼠异种移植瘤模型中显著抑制肿瘤生长。A)化合物IB-1分别在60mg/kg(1次/天)、40mg/kg(2次/天,bid)剂量,口服给药,连续给药10天,肿瘤生长均被显著抑制;B)在给药过程中,给药组小鼠体重均未出现明显变化,表明对小鼠对药物有较好的耐受,IB-1无明显毒副作用。As shown in Figure 1, compound IB-1 significantly inhibited tumor growth in EML4-ALK(G1202R)-Ba/F3 nude mouse xenograft tumor model. A) Compound IB-1 was administered orally at 60 mg/kg (1 time/day) and 40 mg/kg (2 times/day, bid), respectively, for 10 consecutive days, the tumor growth was significantly inhibited; B) During the administration process, the body weight of the mice in the administration group did not change significantly, indicating that the mice had a good tolerance to the drug, and IB-1 had no obvious side effects.
2.化合物IB-1在H3122肿瘤细胞裸鼠异种移植瘤模型中显著抑制肿瘤生长(图2)2. Compound IB-1 significantly inhibited tumor growth in H3122 tumor cell nude mouse xenograft tumor model (Figure 2)
本次试验动物选用BALB/c(nu/nu)裸鼠,雌雄各半,4~6周龄,体重约18±2g,SPF级环境饲养,严格无菌操作。实验动物提前1周适应实验环境,自由取食饮水,保持12h昼夜节律。The experimental animals were BALB/c (nu/nu) nude mice, half male and half male, 4 to 6 weeks old, weighing about 18 ± 2 g, raised in an SPF environment, and subjected to strict aseptic operation. The experimental animals were acclimated to the experimental environment one week in advance, had free access to food and water, and maintained a 12-h circadian rhythm.
实验所用NCI-H3122细胞选用PRMI-1640培养液加入10%胎牛血清培养,细胞放置于37℃,5%CO2培养箱环境。The NCI-H3122 cells used in the experiment were cultured with PRMI-1640 medium and 10% fetal bovine serum, and the cells were placed in a 37°C, 5% CO 2 incubator environment.
胞接种法建立肿瘤裸鼠皮下移植模型:过滤收集对数生长期细胞,离心后用PBS清洗,用PRMI-1640培养液重悬为单细胞悬液,按每只裸鼠5×106/200μL细胞量。用1mL注射器(4.5号针头)在裸鼠右前腋附近皮下注射细胞悬液。当荷瘤小鼠肿瘤长到可测量大小时开始每日测量计算瘤体积,在肿瘤体积达到150mm3左右时随机将小鼠进行分组,每组5只,共四组,分组当日开始给药。给药组分为IB-1 30mg/kg(1次/天),50mg/kg(1次/天),阳性对照组给Crizotinib 50mg/kg(1次/天),阴性对照组给等量溶剂,连续给药18天。试验期间隔天测定动物体重和肿瘤大小,每日观察记录小鼠状态,最后一次给药6h后用5%的水合氯醛麻醉处死小鼠,取肿瘤,称重并拍照记录。肿瘤体积(Tumor Volume,TV)的计算公式为:TV=1/2×a×b2,其中a,b分别表示肿瘤长径和短径。The tumor nude mouse subcutaneous transplantation model was established by the cell inoculation method: the cells in the logarithmic growth phase were collected by filtration, washed with PBS after centrifugation, and resuspended in PRMI -1640 medium to form a single cell suspension. amount of cells. The cell suspension was subcutaneously injected near the right anterior axilla of nude mice with a 1 mL syringe (4.5 gauge needle). When the tumor of the tumor-bearing mice grew to a measurable size, the tumor volume was measured and calculated every day. When the tumor volume reached about 150 mm 3 , the mice were randomly divided into groups, with 5 mice in each group, with a total of four groups. The administration components were IB-1 30mg/kg (1 time/day), 50mg/kg (1 time/day), Crizotinib 50mg/kg (1 time/day) for the positive control group, and the same amount of solvent for the negative control group , for 18 consecutive days. During the test period, the body weight and tumor size of the animals were measured every day, and the state of the mice was observed and recorded every day. The mice were anesthetized with 5% chloral hydrate 6 hours after the last administration, and the tumors were taken out, weighed, and photographed for recording. The formula for calculating tumor volume (TV) is: TV=1/2×a×b 2 , where a and b represent the long and short diameters of the tumor, respectively.
如图2所示,化合物IB-1在非小细胞肺癌H3122细胞裸鼠异种移植瘤模型中显著抑制肿瘤生长。A)化合物IB-1分别在30mg/kg(1次/天)、50mg/kg(1次/天)剂量,口服给药,连续给药18天,肿瘤生长均被显著抑制;B)在给药过程中,给药组小鼠体重均未出现明显变化,表明对小鼠对药物有较好的耐受,IB-1无明显毒副作用。As shown in Figure 2, compound IB-1 significantly inhibited tumor growth in a nude mouse xenograft tumor model of non-small cell lung cancer H3122 cells. A) Compound IB-1 was administered orally at doses of 30 mg/kg (1 time/day) and 50 mg/kg (1 time/day), respectively, for 18 consecutive days, the tumor growth was significantly inhibited; B) After administration During the course of the drug, the body weight of the mice in the administration group did not change significantly, indicating that the mice had a good tolerance to the drug, and IB-1 had no obvious toxic and side effects.
以上所述的仅是本发明的一些实施方式。对于本领域的普通技术人员来说,在不脱离本发明创造构思的前提下,还可以做出若干变形和改进,这些都属于本发明的保护范围。The foregoing are merely some of the embodiments of the present invention. For those of ordinary skill in the art, without departing from the inventive concept of the present invention, several modifications and improvements can be made, which all belong to the protection scope of the present invention.
Claims (43)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710907030.4A CN109575045B (en) | 2017-09-28 | 2017-09-28 | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof |
TW106136612A TWI780077B (en) | 2017-09-28 | 2017-10-25 | Thienopyrimidine compound, its preparation method, pharmaceutical composition and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710907030.4A CN109575045B (en) | 2017-09-28 | 2017-09-28 | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109575045A CN109575045A (en) | 2019-04-05 |
CN109575045B true CN109575045B (en) | 2021-02-12 |
Family
ID=65914773
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710907030.4A Active CN109575045B (en) | 2017-09-28 | 2017-09-28 | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN109575045B (en) |
TW (1) | TWI780077B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021098883A1 (en) * | 2019-11-21 | 2021-05-27 | 浙江同源康医药股份有限公司 | Compound used as egfr kinase inhibitor and use thereof |
CN113717156B (en) * | 2020-05-25 | 2023-05-09 | 南京红云生物科技有限公司 | EGFR inhibitor, preparation method and application thereof |
BR112022024937A2 (en) * | 2020-06-08 | 2022-12-27 | Hongyun Biotech Co Ltd | ALKENYLPYRMIDINE COMPOUND, METHOD OF PREPARATION AND APPLICATION OF THE SAME |
CN114105887B (en) * | 2021-09-16 | 2023-12-01 | 沈阳药科大学 | Aminopyrimidine derivative and preparation method and application thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003055890A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
JP2008013527A (en) * | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | THIENO[3,2-d]PYRIMIDINE-2,4-DIAMINE DERIVATIVE |
CN102947316A (en) * | 2010-06-23 | 2013-02-27 | 韩美科学株式会社 | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
CN103242341A (en) * | 2013-04-19 | 2013-08-14 | 中国科学院广州生物医药与健康研究院 | Thieno 2,4-substituted pyrimidine compound, and pharmaceutical composition and application thereof |
CN106188060A (en) * | 2015-04-29 | 2016-12-07 | 厦门大学 | Pyrimido azoles, its preparation method, Pharmaceutical composition and application thereof |
CN107698603A (en) * | 2016-08-09 | 2018-02-16 | 厦门大学 | Thienopyrimidines, its preparation method, Pharmaceutical composition and its application |
-
2017
- 2017-09-28 CN CN201710907030.4A patent/CN109575045B/en active Active
- 2017-10-25 TW TW106136612A patent/TWI780077B/en active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003055890A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Thienopyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
JP2008013527A (en) * | 2006-07-10 | 2008-01-24 | Sankyo Co Ltd | THIENO[3,2-d]PYRIMIDINE-2,4-DIAMINE DERIVATIVE |
CN102947316A (en) * | 2010-06-23 | 2013-02-27 | 韩美科学株式会社 | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
CN103242341A (en) * | 2013-04-19 | 2013-08-14 | 中国科学院广州生物医药与健康研究院 | Thieno 2,4-substituted pyrimidine compound, and pharmaceutical composition and application thereof |
CN106188060A (en) * | 2015-04-29 | 2016-12-07 | 厦门大学 | Pyrimido azoles, its preparation method, Pharmaceutical composition and application thereof |
CN107698603A (en) * | 2016-08-09 | 2018-02-16 | 厦门大学 | Thienopyrimidines, its preparation method, Pharmaceutical composition and its application |
Non-Patent Citations (1)
Title |
---|
Antiproliferative activities of halogenated thieno[3,2-d]pyrimidinese;Kartik W. Temburnikar et al.;《Bioorganic & Medicinal Chemistry》;20140303;第22卷(第7期);第2115页Scheme 2 * |
Also Published As
Publication number | Publication date |
---|---|
CN109575045A (en) | 2019-04-05 |
TWI780077B (en) | 2022-10-11 |
TW201915004A (en) | 2019-04-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107698603B (en) | Thienopyrimidine compound, its preparation method, pharmaceutical composition and its application | |
CA3054455C (en) | Fgfr inhibitor and application thereof | |
US6608056B1 (en) | Fused heteroaryl derivatives | |
EP1277738B1 (en) | Condensed heteroaryl derivatives | |
KR101828187B1 (en) | Novel fused pyrimidine compound or salt thereof | |
KR20170069199A (en) | Indazole compounds as fgfr kinase inhibitor, preparation and use thereof | |
WO2022135432A1 (en) | Macrocyclic heterocyclic compounds as egfr inhibitors, and use thereof | |
IL311024A (en) | Substituted tricyclic compounds as parp inhibitors and use thereof | |
US10085983B2 (en) | Azabicyclo derivatives, process for preparation thereof and medical use thereof | |
CN109575045B (en) | Thienopyrimidine compound, preparation method thereof, medicinal composition and application thereof | |
JP2023525656A (en) | EGFR inhibitor, method of preparation and use thereof | |
TW202400601A (en) | Substituted tricyclic compounds as parp inhibitors and the use thereof | |
CN110770234B (en) | Substituted aryl ether compound, its preparation method, pharmaceutical composition and application thereof | |
AU2020342189A1 (en) | 3, 5-disubstituted pyrazole compounds as kinase inhibitors and uses thereof | |
WO2022218296A1 (en) | Substituted fused bicyclic compounds as parp inhibitors and the use thereof | |
CN115697996A (en) | Alkenyl pyrimidine compound, preparation method and application thereof | |
WO2021004482A1 (en) | Substituted pyrazoloquinazolone compound and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20240129 Address after: Siming District of Xiamen city in Fujian Province, 361005 South Siming Road No. 422 Patentee after: XIAMEN University Country or region after: China Address before: 211112 Longmian Avenue 568, Jiangning District, Nanjing City, Jiangsu Province Patentee before: NANJING HONGYUN BIO-TECH Co.,Ltd. Country or region before: China |